Generated by All in One SEO v4.9.3, this is an llms.txt file, used by LLMs to index the site.

# Venture Valuation

Global Valuation Services

## Sitemaps

- [XML Sitemap](https://venturevaluation.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Venture Valuation and Biotechgate to participate in the 2026 BIO International Convention in San Diego](https://venturevaluation.com/2026/06/venture-valuation-and-biotechgate-to-participate-in-the-2026-bio-international-convention-in-san-diego/) - ZURICH, Switzerland, June 2026 – Venture Valuation and Biotechgate will participate in the 2026 BIO International Convention, taking place June 22–25, 2026, at the San Diego Convention Center, as well as the RESI Conference at the JULEP Venue in San Diego on June 22. The team will be available at booth 2111 in the Swiss
- [Interviews with leading Life Sciences companies: K Pharma](https://venturevaluation.com/2026/05/interviews-with-leading-life-sciences-companies-k-pharma/) - K Pharma is demonstrating the unprecedented iPSC (induced Pluripotent Stem Cell) based drug discovery technology for more effective treatment of ALS (Amyotrophic Lateral Sclerosis). Learn more about the Tokyo-based organization in this installment of our Let's Interview Series. Venture Valuation (VV) interviewed MATSUMOTO Masato, CFO. Read the Interview (PDF) Would you like to be notified
- [PLCD 2026: Valuation for Licensing](https://venturevaluation.com/2026/04/plcd-2026-valuation-for-licensing/) - Presented by Dr. Darren Leneghan at Pharma Licensing Club Germany (PLCD), Frankfurt, April 2026. Download the Presentation (PDF)
- [BioTrinity 2026: A Guide to Valuation for Licensing to Pharma](https://venturevaluation.com/2026/04/biotrinity-2026-a-guide-to-valuation-for-licensing-to-pharma/) - Presented by Dr. Patrik Frei at BioTrinity, London, April 2026. Download the Presentation (PDF)
- [RESI Europe 2026: Company Valuation](https://venturevaluation.com/2026/03/resi-europe-2026-company-valuation/) - Presented by Dr. Patrik Frei at RESI Europe, Lisbon, March 2026. Download the Presentation (PDF)
- [Venture Valuation Launches Redesigned Website with Enhanced User Experience](https://venturevaluation.com/2026/02/venture-valuation-launches-redesigned-website-with-enhanced-user-experience/) - ZURICH, SWITZERLAND - February 26, 2026 - Venture Valuation, a leading independent provider of valuation services for the global life sciences industry, today announced the launch of its newly redesigned website at VentureValuation.com. The new site features a completely modernized and cleaner design, significantly improving the user interface and overall user experience. The update reflects Venture
- [Inaugural Pre-JPM Partnering Week to Wrap Up 2024, Prepare for 2025](https://venturevaluation.com/2024/08/9041/) - Virtual conference Dec 2-6, 2024, prepares life science dealmakers ahead of the 2025 J.P. Morgan Health Conference SAN FRANCISCO and ZURICH, Switzerland, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Big4Bio and Biotechgate are proud to announce the launch of a new annual conference for the life science industry, Pre-JPM Partnering Week, presented virtually Dec 2-6, 2024.
- [Interviews with leading Life Sciences companies: Toregem Biopharma](https://venturevaluation.com/2024/11/interviews-with-leading-life-sciences-companies-toregem-biopharma/) - Toregem is aiming to commercialize a groundbreaking antibody drug for tooth regeneration. Learn more about the Kyoto-based organization in this installment of our Let's Interview Series. Venture Valuation (VV) interviewed Dr. KISO Honoka, D.D.S., Ph.D., Co-founder and CEO. Read the Interview (PDF) Would you like to be notified about new interviews, reports and other valuable
- [Venture Valuation/Biotechgate Announces Strategic Partnership with BioFlorida to Enhance USA Life Sciences Database](https://venturevaluation.com/2024/11/venture-valuation-biotechgate-announces-strategic-partnership-with-bioflorida-to-enhance-usa-life-sciences-database/) - ZURICH, Switzerland, November 2024 – Biotechgate, a leading provider of life sciences information and partnering solutions, is pleased to announce its strategic collaboration with BioFlorida. This partnership aims to strengthen the data integration in Biotechgate while enhancing the visibility and insights of the life sciences industry in Florida. As a key initiative of this new
- [5 Ways to Make the Most of Your Next Partnering Conference](https://venturevaluation.com/2024/11/5-ways-to-make-the-most-of-your-next-partnering-conference/) - Partnering conferences, virtually or in-person, offer companies invaluable opportunities for networking, uncovering potential partners, and advancing business growth. Whether you’re attending an event with the aim to secure funding, learn about new innovations, or build a list of potential collaborators, these events require thoughtful preparation. In today’s dynamic biotech and life sciences sector, partnering conferences
- [The Most Important Features in Biotechgate Digital Partnering](https://venturevaluation.com/2024/11/the-most-important-features-in-biotechgate-digital-partnering/) - Biotechgate Digital Partnering is a quarterly virtual conference series that allows participants to connect with fellow life science professionals to find their next partner, deal or collaboration. The event takes place on HelloPartnering, a platform that allows participants to easily identify prospects to contact and schedule one-on-one meetings with. In this article, you’ll find a
- [How to Create a Winning Pitch for Your Life Science Company](https://venturevaluation.com/2024/11/how-to-create-a-winning-pitch-for-your-life-science-company/) - Creating an effective pitch that wins over an investor that engages investors is essential for life science companies of all stages, whether early or established Life science pitches are unique in their need to blend scientific depth with business viability, balancing technical details with clarity. This article provides insights into the essential elements of a
- [A Guide to Sending More Effective Meeting Requests](https://venturevaluation.com/2024/11/a-guide-to-sending-more-effective-meeting-requests/) - In the fast-paced life sciences sector, securing meaningful meetings with potential partners, clients or investors is paramount when on the conference circuit. However, standing out among a sea of requests can be challenging. Here’s how to craft meeting requests that lead to successful engagements so you can secure a deal. 1. Personalize Your Message Generic
- [Venture Valuation/Biotechgate to Attend JPM Week in San Francisco, Featuring Presentation by CEO Dr. Patrik Frei](https://venturevaluation.com/2024/12/venture-valuation-biotechgate-to-attend-jpm-week-in-san-francisco-featuring-presentation-by-ceo-dr-patrik-frei/) - ZURICH, Switzerland, December 2024 – Venture Valuation/Biotechgate (the “Company”) a leader in life science valuation and data solutions, is pleased to announce its participation in JPM Week 2025, taking place in San Francisco this January. The week, centered around the J.P. Morgan Healthcare Conference, is one of the most significant gatherings in the life sciences
- [Interviews with leading Life Sciences companies: Metagen Therapeutics](https://venturevaluation.com/2025/01/interviews-with-leading-life-sciences-companies-metagen-therapeutics/) - Metagen Therapeutics is investigating the safety and efficacy of Antibiotic Fecal Microbiota Transplantation (A-FMT) in patients with advanced-stage Parkinson’s disease for microbiome therapeutics development. Learn more about the Yamagata-based organization in this installment of our Let's Interview Series. Venture Valuation (VV) interviewed Dr. NAKAHARA Taku, President and CEO. Read the Interview (PDF) Would you like
- [RESI JPM 2025 Workshop: Company Valuation](https://venturevaluation.com/2025/01/resi-jpm-2025-workshop-company-valuation/) - Presented by Dr. Patrik Frei at RESI JPM, San Francisco, January 2025. View the presentation (PDF)
- [Introduction to Venture Valuation](https://venturevaluation.com/2025/02/vv_presentation2025/) - Vv_presentation_2025Download
- [BioTrinity 2025: A Guide to Valuation for Fundraising](https://venturevaluation.com/2025/04/biotrinity-2025-a-guide-to-valuation-for-fundraising/) - Presented by Dr. Patrik Frei at BioTrinity, London, April 2025. View the Presentation (PDF)
- [Interviews with leading Life Sciences companies: EVA Therapeutics](https://venturevaluation.com/2025/04/interviews-with-leading-life-sciences-companies-eva-therapeutics/) - EVA Therapeutics is primarily focused on rescuing premature newborn babies with respiratory distress syndrome by developing an unprecedented enteral ventilation technology. Learn more about the Osaka-based organization in this installment of our Let's Interview Series. Venture Valuation (VV) interviewed OZAKI Hiromu, Co-founder and CEO. Read the Interview (PDF) Would you like to be notified about
- [Venture Valuation and Biotechgate to participate in the 2025 BIO International Convention in Boston](https://venturevaluation.com/2025/06/venture-valuation-and-biotechgate-to-participate-in-the-2025-bio-international-convention-in-boston/) - ZURICH, Switzerland, June 2025 – Venture Valuation/Biotechgate (the “Company”) is delighted to announce its participation in the highly anticipated 2025 BIO International Convention taking place June 16-19, 2025, at the Boston Convention & Exhibition Center, in Boston, USA, as well as at RESI (Redefining Every Stage of Investment) Seed to Exit, at The Westin Copley
- [Interviews with leading Life Sciences companies: Organoid Farm](https://venturevaluation.com/2025/09/interviews-with-leading-life-sciences-companies-organoid-farm/) - By applying organoid technology and its proprietary immortalized bovine muscle cell lines by genetic modification, Organoid Farm is determined to play a crucial role in developing a new food supply chain for cultured meat. Learn more about the Kanagawa-based organization in this installment of our Let's Interview Series. Venture Valuation (VV) interviewed Taeko Yamaki, CEO.
- [Interviews with leading Life Sciences companies: AMS](https://venturevaluation.com/2025/09/interviews-with-leading-life-sciences-companies-ams/) - AMS is the developer of BSL-177, the world’s first compact system that treats radioactive urine from nuclear medicine patients, protecting staff, patients, and the environment from contamination. Learn more about the Tokyo-based organization in this installment of our Let's Interview Series. Venture Valuation (VV) interviewed SUGAWARA Yuichiro, Founder, President and CEO. Read the Interview (PDF)
- [World Vaccine Congress Europe: Company Valuation](https://venturevaluation.com/2025/10/world-vaccine-congress-europe-company-valuation/) - Presented by Dr. Darren Leneghan at World Vaccine Congress Europe, Amsterdam, October 2025. View the presentation (PDF)
- [Biotech Summit Austria 2025: Valuing Biotech Companies for Financing and Partnering](https://venturevaluation.com/2025/10/biotech-summit-austria-2025-valuing-biotech-companies-for-financing-and-partnering/) - Presented by Dr. Patrik Frei at Biotech Summit Austria, Graz, October 2025. Download the Presentation (PDF)
- [Venture Valuation/Biotechgate to Attend JPM Week in San Francisco](https://venturevaluation.com/2025/12/venture-valuation-biotechgate-to-attend-jpm-week-in-san-francisco/) - ZURICH, Switzerland, December 2025 – Venture Valuation/Biotechgate (the “Company”) a leader in life science valuation and data solutions, is pleased to announce its participation in JPM Week 2026, taking place in San Francisco this January. The week, centered around the J.P. Morgan Healthcare Conference, is one of the most significant gatherings in the life sciences
- [Interviews with leading Life Sciences companies: Pharma Foods International](https://venturevaluation.com/2026/01/interviews-with-leading-life-sciences-companies-pharma-foods-international/) - Pharma Foods International is developing and commercializing the world's first textile fiber material from discarded chicken eggshell membrane: ovoveil®. Learn more about the Kyoto-based organization in this installment of our Let's Interview Series. Venture Valuation (VV) interviewed HARADA Seiyu Ph.D, General Manager of the Corporate Strategy Department. Read the Interview (PDF) Would you like to
- [Dr. Patrik Frei Delivers a Webinar to Harvard Business School Alumni](https://venturevaluation.com/2017/06/dr-patrik-frei-delivers-a-webinar-to-harvard-business-school-alumni/) - On 7th of June 2017, CEO of Venture Valuation, Dr Patrik Frei, delivered a live webinar titled 'Valuation of Life Sciences Start-up' to healthcare alumni of Harvard Business School. The online event was a part of Healthcare Roundtable, a series of interactive presentations by industry leaders organised by HBS Healthcare Alumni Association. Dr. Frei talked about the significance
- [Valuation of Life Sciences Start-up - Questions and Answers](https://venturevaluation.com/2017/07/valuation-of-life-sciences-start-up-questions-and-answers/) - Last month, CEO of Venture Valuation, Dr Patrik Frei, delivered a live webinar titled ‘Valuation of Life Sciences Start-up’ to healthcare alumni of Harvard Business School You can watch the webinar here. Due to a large number of questions from participants, not all of them could be answered during the event. In this post, we
- [What is the value of a deal?](https://venturevaluation.com/2016/06/what-is-the-value-of-a-deal/) - Venture Valuations Dr. Aitana Peire and Dr. Patrik Frei have published an article “What is the value of a deal?” in Nature Publishing Groups’. The article is available online as well as in the biopharmadealmakers supplement June 2016 edition of nature biotechnology and Nature Reviews Drug Discovery. The pharmaceutical and biotechnology industries see over 3,000
- [Interviews with leading Life Sciences companies: Megakaryon](https://venturevaluation.com/2024/08/interviews-with-leading-life-sciences-companies-megakaryon/) - Megakaryon is aiming for mass production of the first global iPSC (induced Pluripotent Stem Cell)-derived platelet product for allogeneic use. Learn more about the Kyoto-based organization in this installment of our Let's Interview Series. Venture Valuation (VV) interviewed Dr. AKAMATSU Kenichi, CEO, and Mr. AYABE Tsuyoshi, COO & CFO. Read the Interview (PDF) Would you
- [Venture Valuation and Biotechgate to Participate in the 2024 BIO International Convention in San Diego](https://venturevaluation.com/2024/05/venture-valuation-and-biotechgate-to-participate-in-the-2024-bio-international-convention-in-san-diego/) - ZURICH, Switzerland, May 2024 – Venture Valuation/Biotechgate (the “Company”) is delighted to announce its participation in the highly anticipated 2024 BIO International Convention taking place June 3-6, 2024, at the San Diego Convention Center, in San Diego, California, USA. The annual BIO International Convention, hosted by Biotechnology Innovation Organization (BIO), is the world’s largest industry
- [Interviews with leading Life Sciences companies: Sound Wave Innovation](https://venturevaluation.com/2024/05/interviews-with-leading-life-sciences-companies-sound-wave-innovation/) - Sound Wave Innovation is developing proprietary LIPUS (Low-Intensity Pulsed Ultrasound) brain therapy, focusing on early-stage Alzheimer's disease. Learn more about the Tokyo-based organization in this installment of our Let's Interview Series. Venture Valuation (VV) interviewed Dr. SHIMOKAWA Hiroaki, Founder & CMO, KATO Hajime, CEO, and MANO Takamitsu, Corporate Director. Read the Interview (PDF) Would you
- [Interviews with leading Life Sciences companies: Pixie Dust Technologies](https://venturevaluation.com/2024/01/interviews-with-leading-life-sciences-companies-pixie-dust-technologies/) - Pixie Dust Technologies invented a new audio method with gamma wave sound to prevent or even improve Alzheimer’s disease. Learn more about the Tokyo-based organization in this installment of our Let's Interview Series. Venture Valuation (VV) interviewed TSUJI Mitsutaka, General Manager, and NAGATANI Yoshiki, PhD, Senior Engineer. Read the Article (PDF) Would you like to
- [Venture Valuation/Biotechgate Announces Participation in Biotech Showcase, the J.P. Morgan 41st Annual Healthcare Conference 2024 and RESI](https://venturevaluation.com/2023/12/venture-valuation-biotechgate-announces-participation-in-biotech-showcase-the-j-p-morgan-41st-annual-healthcare-conference-2024-and-resi/) - ZURICH, Switzerland, December 2023 – Venture Valuation/Biotechgate (the “Company”) is delighted to announce its participation at Biotech Showcase and Redefining Early Stage Investments (RESI) alongside the J.P. Morgan 41st Annual Healthcare Conference 2024. During the aforementioned events, the Company team will conduct one-to-one meetings discussing their independent valuation services, life sciences database, and quarterly partnering
- [Venture Valuation Strengthens its Presence in North America With Sales Team Expansion](https://venturevaluation.com/2023/12/venture-valuation-strengthens-its-presence-in-north-america-with-sales-team-expansion/) - Zurich, Switzerland, December 2023 – Venture Valuation announces that it has appointed Bill Colihan and David Tucker as BD Directors to strengthen its expansion in North America. The new appointments' primary focus will be on Venture Valuation's Biotechgate database, a unique business development and licensing platform for the life sciences industry. Both BD directors are
- [Interviews with leading Life Sciences companies: Rebirthel](https://venturevaluation.com/2023/11/interviews-with-leading-life-sciences-companies-rebirthel/) - Rebirthel are preparing the first clinical trial conducted in humans for acute myeloid leukemia to evaluate safety and efficacy. Learn more about the Kyoto-based organization in this installment of our Let's Interview Series. Venture Valuation (VV) interviewed President and CEO, Mr. Kajikawa Masunori. Read the Article Would you like to be notified about new interviews,
- [Life Sciences M&A Report: Half-Year 2023](https://venturevaluation.com/2023/10/life-sciences-ma-report-half-year-2023/) - In the first half of 2023, the slowdown in terms of global life sciences M&A deal-making experienced in the second half of 2022 has continued to show its effects. Anticipated as a year of recovery, 2023 was expected to leverage M&A as a means to adapt to rapidly changing market conditions. However, while it remains
- [ライフサイエンス 企業： 欧州事業拠点の 立地選定](https://venturevaluation.com/2023/10/ライフサイエンス-企業：-欧州事業拠点の-立地選/) - ライフ サイエンス事業を立ち上げたり拡大したりする際に、適切な場所を選択するのは簡単なことではありません。 Venture Valuation との協力により KPMG が作成したこのレポートでは、欧州における事業拠点選定プロセスの概要と、各国の包括的分析内容を提供いたします。 レポートを読む
- [Site Selection for Life Sciences Companies in Europe](https://venturevaluation.com/2023/10/site-selection-for-life-sciences-companies-in-europe/) - Choosing the right location when setting up or expanding your life science operations is no easy task. This report by KPMG, made in cooperation with Venture Valuation, will give you an overview on the site selection process in Europe, complete with insights on individual countries. Read the report >>
- [Interviews with leading Life Sciences companies: Human Life Cord](https://venturevaluation.com/2023/09/interviews-with-leading-life-sciences-companies-human-life-cord/) - Human Life Cord specialize in allogeneic cell therapy, applying umbilical cord derived mesenchymal stromal cells (MSCs) that are able to differentiate into a variety of cell types. Learn more about the Tokyo-based organization in this installment of our Let's Interview Series. Venture Valuation (VV) interviewed President and CEO, Mr. Harata Masamitsu. Read the Article Would
- [Venture Valuation/Biotechgate and One Nucleus Partner to Boost Life Sciences Connectivity and Innovation](https://venturevaluation.com/2023/09/venture-valuation-biotechgate-and-one-nucleus-partner-to-boost-life-sciences-connectivity-and-innovation/) - Zurich, Switzerland and Cambridge, UK, September 2023 – Biotechgate, a leading global life sciences business development and licensing database and One Nucleus, a Cambridge, UK-based life sciences and healthcare membership organisation, are thrilled to announce a collaboration to boost life sciences connectivity and innovation. The purpose of this collaboration is to provide a reliable hub
- [A Formula for Drug Licensing Deals](https://venturevaluation.com/2023/09/a-formula-for-drug-licensing-deals/) - Venture Valuation's Elias Neuendorf, Kara E. O’Connell, Patrik Frei and Kumlesh Kumar Dev recently had article published as part of Nature's Biopharma Dealmakers publication, covering the topic of "A formula for drug licensing deals". Find out how a mathematical model can predict the total value of licensing deals. Read the full article »
- [Interviews with leading Life Sciences companies: Sonire Therapeutics](https://venturevaluation.com/2023/08/interviews-with-leading-life-sciences-companies-sonire-therapeutics/) - Sonire Therapeutics has commenced a randomized Phase 2 study for the treatment of unresectable pancreatic cancer with their next-generation High-Intensity Focused Ultrasound therapy system. Learn more about the Tokyo-based organization in this installment of our Let's Interview Series. Venture Valuation (VV) interviewed President and CEO, Mr. Satoh Toru. Read the Interview Would you like to
- [Venture Valuation/Biotechgate and AdvaMed Team Up to Drive MedTech Industry Growth](https://venturevaluation.com/2023/08/venture-valuation-biotechgate-and-advamed-team-up-to-drive-medtech-industry-growth/) - Media Release Zurich, Switzerland and Washington, D.C., USA, August 2023 – Biotechgate, a global business development and licensing database for the life sciences industry, is proud to announce its strategic partnership with the Advanced Medical Technology Association (AdvaMed). This collaboration aims to strengthen the data integration in Biotechgate, while enhancing the visibility and insight into
- [RESI Conference June 2023 – Company Valuation for Fundraising & Financing and M&A trends](https://venturevaluation.com/2023/06/resi-conference-june-2023-company-valuation-for-fundraising-financing-and-ma-trends/) - RESI, Boston, June 2023, 32 pages Presentation View presentation
- [Venture Valuation and Biotechgate to participate in the 2023 BIO International Convention in Boston](https://venturevaluation.com/2023/05/venture-valuation-and-biotechgate-to-participate-in-the-2023-bio-international-convention-in-boston/) - ZURICH, Switzerland, May 2023 – Venture Valuation/Biotechgate (the “Company”) is delighted to announce its participation in the highly anticipated 2023 BIO International Convention taking place June 5-8, 2023, at the Boston Convention & Exhibition Center, in Boston, Massachusetts, USA. The Company welcomes attendees to visit their booth at booth number 1743 in the Swiss Pavilion
- [Interviews with leading Life Sciences companies: J-Pharma](https://venturevaluation.com/2023/05/interviews-with-leading-life-sciences-companies-j-pharma/) - J-Pharma is a frontrunner in developing inhibitors of L-type amino acid transporter for treating advanced refractory cancers and autoimmune diseases. Learn more about the Yokohama-based organization in this installment of our Let's Interview Series. Venture Valuation (VV) interviewed President and CEO, Mr. Max Yoshitake. Read the Interview Would you like to be notified about new
- [Interviews with leading Life Sciences companies: Aipore](https://venturevaluation.com/2023/02/interviews-with-leading-life-sciences-companies-aipore/) - Aipore is developing AI-enabled solid-state nanospore sensor technology that can detect SARS-CoV2 coronavirus in saliva specimens within 5 minutes. Learn more about the Tokyo-based organization in this installment of our Let's Interview Series. Venture Valuation (VV) interviewed Founder and CEO, Mr. Naono Norihiko. Read the interview Would you like to be notified about new interviews,
- [Venture Valuation/Biotechgate Partners with ALLIS-NA: Launch of Member Directory](https://venturevaluation.com/2023/05/venture-valuation-biotechgate-partners-with-allis-na-launch-of-member-directory/) - Media Release Venture Valuation/Biotechgate Partners with ALLIS-NA: Launch of Member Directory Zurich, Switzerland and Paris, France, March 2023 – Venture Valuation/Biotechgate is proud to announce its partnership with the French regional health cluster Alliance Innovation Santé Nouvelle-Aquitaine (ALLIS-NA). The two organizations are collaborating to accelerate both the data integration in Biotechgate and economic development of
- [Enterprise Lithuania becomes a partner of Venture Valuation/Biotechgate](https://venturevaluation.com/2021/01/enterprise-lithuania-becomes-a-partner-of-venture-valuation-biotechgate/) - Media release Enterprise Lithuania becomes a partner of Venture Valuation/Biotechgate Zurich / Vilnius, Jan 2021 Venture Valuation/Biotechgate announce a cooperation with Enterprise Lithuania, trade promotion governmental agency. As per the agreement of the two parties, the Lithuanian Biotech Database has been set-up, a regional portal integrated with Biotechgate Business Development Database. Access to the portal
- [Interviews with leading Life Sciences companies: Varinos Inc.](https://venturevaluation.com/2022/10/interviews-with-leading-life-sciences-companies-varinos-inc/) - Varinos commercialized the world’s first highly accurate endometrial microbiome testing service by applying next-generation sequencing. Learn more about the Tokyo-based organization in this installment of our Let's Interview Series. Venture Valuation (VV) interviewed Founder and CEO, Dr. Sakuraba Yoshiyuki. Read the Interview Would you like to be notified about new interviews, reports and other valuable
- [BIO IP & Diagnostics Symposium (IPDx) Keynote Session](https://venturevaluation.com/2017/10/valuation-of-life-sciences-companies/) - Dr. Patrik Frei was the keynote speaker at BIO IP & Diagnostics Symposium (IPDx) on 29th of September 2017. During the session, the Venture Valuation CEO discussed the valuation of biotechnology companies and products and its link to IP. He gave a short introduction to risk-adjusted net present value calculations, the main value drivers and
- [Trends and facts on licensing deals](https://venturevaluation.com/2020/11/trends-and-facts-on-licensing-deals/) - Workshop about trends and facts on licensing deals. Presented at Biotechgate Digital Partnering November 2020 by Venture Valuation's Dr. Patrik Frei and Elias Neuendorf. Presentation
- [The World's First Drug Discovery Platform Using Quantum Computing - POLARISqb](https://venturevaluation.com/2022/06/the-worlds-first-drug-discovery-platform-using-quantum-computing-polarisqb/) - Founded in 2020 and winners of the XY Factor competition at Biotechgate Digital Partnering February 2022, POLARISqb have built the first ever drug discovery platform using a quantum computer - Tachyon™ - to shorten the years-long preclinical drug design and optimization process to just a few months. Venture Valuation (VV) interviewed CEO and co-founder, Shahar
- [Yone Production Co. Ltd., Succeeded, on the world’s first attempt](https://venturevaluation.com/2021/09/yone-production-co-ltd-succeeded-on-the-worlds-first-attempt/) - Established by KOBAYASHI Yonesaku, a well-known documentary cameraman and pioneer of cinephotomicrography, and Dr ASAKA Tokio, anatomist and expert in biological sample research and development, Yone Production has played a vital role over 50 years in supporting scientific advancement and promoting scientific films. Venture Valuation (VV) interviewed FUJIEDA Ayumi, CEO. Read the Interview Would you
- [Heartseed Inc., Breakthrough cell therapy for severe heart failure.](https://venturevaluation.com/2022/01/heartseed-inc-breakthrough-cell-therapy-for-severe-heart-failure/) - As an innovative new treatment option for heart failure, a unique cardiac remuscularization therapy has been invented by Dr. FUKUDA Keiichi, Founder & CEO, Professor at Keio University School of Medicine. Venture Valuation (VV) interviewed YASUI Kikuo, COO. Read the Interview Would you like to be notified about new interviews, reports and other valuable content
- [New treatment modality for amyloidosis related diseases - Vermilion Therapeutics](https://venturevaluation.com/2022/04/new-treatment-modality-for-amyloidosis-related-diseases-vermilion-therapeutics/) - Developing a promising therapeutic technology which may contribute to treat various amyloidosis related diseases, incl. Alzheimer’s Disease. Venture Valuation (VV) interviewed TORII Shin-ichi, Ph.D., founder and CEO. Read the Interview Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?
- [How to assess start-up companies](https://venturevaluation.com/2021/12/how-to-assess-start-up-companies/) - Relevant soft factors to assess startup companies Investing in early-stage companies is a risky business. Many venture capitalists have fallen victim to the consequences of a myopic attitude towards thorough risk assessments. Although the negative experiences tend to be heard first, it’s the success stories that make it all the more worthwhile. Before taking the
- [Resi Conference September 2021 - Company Valuation for Fundraising: Trends and Tools](https://venturevaluation.com/2021/09/resi-conference-september-2021-venture-valuation-the-valuation-experts/) - Resi, virtual, September 2021, 31 pages Presentation Presentation
- [RESI Conference June 2021 – Company Valuation for Fundraising: Trends and Tools](https://venturevaluation.com/2021/06/resi-conference-june-2021-company-valuation-for-fundraising-trends-and-tools/) - RESI, virtual, June 2021, 31 pages Presentation Presentation
- [Workshop: Company Valuation for Fundraising - Trends & Tools](https://venturevaluation.com/2021/05/workshop-company-valuation-for-fundraising-trends-tools/) - Venture Valuation held a workshop at the May 2021 edition of Biotechgate Digital Partnering, covering topics such as advice on speaking with investors and valuing a life science company with limited revenue - presented by Dr. Patrik Frei and Dr. Gergely Iványi on May 3rd, 2021. The full workshop can be viewed here, while slides
- [Forty51 Ventures, newly established venture capital firm](https://venturevaluation.com/2021/04/forty51-ventures-newly-established-venture-capital-firm/) - April 2021: Started in Basel by three experienced Partners, Forty51 Ventures targets seed and early-stage investments in underfunded Biotech clusters in Switzerland, Germany, Eastern France, Northern Italy, and Austria. Venture Valuation (VV) interviewed Sascha Oliver Bucher, Co-Founder and Partner. Read the Interview Would you like to be notified about new interviews, reports and other valuable
- [RESI Conference March 2021 - Company Valuation for Fundraising: Trends and Tools](https://venturevaluation.com/2021/03/company-valuation-for-fundraising-trends-and-tools/) - RESI, virtual, March 2021, 31 pages Presentation
- [RESI Conference March 2021 - Product Valuation for Deal-Making](https://venturevaluation.com/2021/03/product-valuation-for-deal-making/) - RESI, virtual, March 2021, 23 pages Presentation
- [Biotech Product Valuation – Setting a Price for Acquisitions](https://venturevaluation.com/2014/11/biotech-product-valuation/) - Big acquisitions like the recent purchase by Roche, Switzerland of Intermune, USA or AbbVie's successful USD 54bn bid for Shire, Ireland, are very good examples of how valuation metrics work and also show that often its not just about price. In case of AbbVie/Shire, potential tax saving was probably the key deal driver. In the
- [RESI Conference June 2019 – Company Valuation for Fundraising](https://venturevaluation.com/2019/06/resi-conference-jun-2019-company-valuation-for-fundraising/) - RESI Conference, Philadelphia, Jun 2019, 26 pages Company Valuation for Fundraising Presentation
- [Interview with Braizon Therapeutics](https://venturevaluation.com/2019/06/interview-with-braizon-therapeutics/) - Applying intelligently glycemic control and a systematic route through the BBB (blood-brain barrier) to effectively reach neurons. Venture Valuation (VV) interviewed the CEO, Mariko Tosu, PhD Read the interview Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?
- [Do Biotech Investors stick to their Home Market?](https://venturevaluation.com/2019/08/do-biotech-investors-stick-to-their-home-market/) - It is no surprise that most biotech investors are based in the US. But, do they invest exclusively in American companies? Read the report Would you like to be notified about new articles, reports and other valuable content published by Venture Valuation?
- [Valuation of biotech companies, assets and products for financing or licensing](https://venturevaluation.com/2019/10/valuation-of-biotech-companies-assets-and-products-for-financing-or-licensing/) - Australia Biotech Invest & Partnering 2019, Melbourne, Oct 2019, 15 pages Deal and Product Valuations
- [Interviews with leading Life Sciences companies: AOT](https://venturevaluation.com/2019/11/interviews-with-leading-life-sciences-companies-aot/) - Founded by four experts in laser physics, medical image analysis, and cranio-maxillofacial surgery, AOT is reinventing the bone surgery field with laser osteotomy technology: CARLO® (Cold Ablation Robotguided Laser Osteotome). Venture Valuation interviewed, Cyrill Bätscher, CEO. Read the interview Would you like to be notified about new interviews, reports and other valuable content published by
- [JPM Conference January 2020 – Company Valuation for Fundraising](https://venturevaluation.com/2020/01/jpm-conference-january-2020-company-valuation-for-fundraising/) - JPM Conference, San Francisco, Jan 2020, 26 pages Company Valuation for Fundraising Presentation
- [Interviews with leading Life Sciences companies: AI Medical Service Inc.](https://venturevaluation.com/2020/02/interviews-with-leading-life-sciences-companies-aim/) - Founded by an accomplished gastroenterologist, AI Medical Service is determined to contribute to the detection of early cancer in the digestive tract by leveraging a CNN deep learning algorithm. Venture Valuation (VV) interviewed Tomohiro Tada, Founder and CEO. Read the interview Would you like to be notified about new interviews, reports and other valuable content
- [The Launch of the Rhine-Main-Neckar Directory](https://venturevaluation.com/2020/03/the-launch-of-the-rhine-main-neckar-directory/) - Zurich 03 March 2020 Last month Biotechgate/Venture Valuation entered a partnership with BioRN, the science and industry cluster of the Rhine-Main-Neckar region, with the goal to develop and run a publicly accessible directory of companies located in the region. The Directory has just been launched and is accessible for free on BioRN’s website. While it
- [Interviews with leading Life Sciences companies: NeU Corporation](https://venturevaluation.com/2020/03/interviews-with-leading-life-sciences-companies-neu-corporation/) - As an industry-university joint venture of Hitachi High Technology Division and Tohoku University Institute of Development, Aging and Cancer, NeU is introducing a unique brain activity measuring device for individual use. Venture Valuation (VV) interviewed Kiyoshi Hasegawa, CEO of NeU. Read the interview Would you like to be notified about new interviews, reports and other
- [Venture Valuation organizes free digital partnering event](https://venturevaluation.com/2020/05/biotechgate-digital-partnering/) - Venture Valuation is organizing a virtual partnering event for biotech, pharmaceutical and medical technology companies from May 18 - 20. With the help of the matchmaking platform HelloPartnering other participants can be contacted and meetings arranged in advance. The basic participation is free of charge.
- [Launch of the Life Science Cluster Member Directory](https://venturevaluation.com/2020/05/launch-of-the-life-science-cluster-member-directory/) - May 2020. Zurich Biotechgate/Venture Valuation and The Life Science Cluster (TLSC) announce that they entered a mutual partnership last month. As per the agreement, Venture Valuation created a member directory that has already been implemented in the TLSC website. It features profiles of all the companies being TLSC members along with a map of the
- [Interviews with leading Life Sciences companies: Lily MedTech Inc.](https://venturevaluation.com/2020/06/interviews-with-leading-life-sciences-companies-lily-medtech-inc/) - May 2020: Founded by a woman engineer caring for women’s health, the 3D whole breast ultrasound diagnostic imaging system demonstrates not only leading-edge technology but also considerate features for examinees. Venture Valuation (VV) interviewed, Mrs. Shiho AZUMA, Founder and CEO. Read the interview Would you like to be notified about new interviews, reports and other
- [Valuation and your financial forecasts](https://venturevaluation.com/2020/06/valuation-and-your-financial-forecasts/) - BIA Life Science Leadership Summit, virtual, Jun 2020, 51 pages Workshop - Deal and Product Valuations
- [Site Selection for Life Sciences Companies in Asia - New Report in Collaboration with KPMG](https://venturevaluation.com/2020/07/site-selection-for-life-sciences-companies-in-asia/) - Zurich / Singapore, July 2020 - In response to the growing need of life sciences companies for comprehensive and unbiased information on various countries and their ability to host key value drivers, KPMG, in collaboration with Venture Valuation has published its report “Site Selection for Life Sciences Companies in Asia” – the first edition. The
- [Launch of the Life Science Directory for Medicen Paris](https://venturevaluation.com/2020/09/launch-of-the-life-science-directory-for-medicen-paris/) - Media Release Launch of the Life Science Directory for Medicen Paris Zurich / Paris, Oct 2020 – Venture Valuation owned Biotechgate announces the partnership with Medicen Paris Region to create a directory of Life Sciences companies. The online directory makes it easier to find partners in one of the key clusters in Europe. Venture Valuation/Biotechgate
- [Interviews with leading Life Sciences companies: FRONTEO Inc.](https://venturevaluation.com/2020/10/interviews-with-leading-life-sciences-companies-fronteo-inc/) - September 2020: Expert in big data analysis primarily in the legal tech business using its NLP AI technology, FRONTEO is applying its knowhow in the fields of life sciences and health care. Venture Valuation (VV) interviewed TOYOSHIBA Hiroyoshi PhD, CTO Life Science AI Business Division, and YAMAMOTO Mari, Member of the Board of Directors. Read
- [Valuation Through A Health Lense & What Professional Investors Look For](https://venturevaluation.com/2020/10/valuation-through-a-health-lense-what-professional-investors-look-for/) - Norway Healthtech, virtual, October 2020, 29 pages Presentation
- [Determine Your Company Valuation With a Little More Confidence](https://venturevaluation.com/2020/11/determine-your-company-valuation-with-a-little-more-confidence/) - Norway Healthtech, virtual, November 2020, 27 pages Presentation
- [Interviews with leading Life Sciences companies: ITO](https://venturevaluation.com/2019/05/interviews-with-leading-life-sciences-companies-ito/) - ITO has developed, since its inception in 1916, high-end professional use therapeutic modalities as well as innovative personal use devices. Venture Valuation (VV) interviewed the COO, Mayuko Ito, great-granddaughter of the founder Kenji Ito. Read the interview Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?
- [Whitepaper: Life Sciences - 409A valuation vs. valuation to raise money](https://venturevaluation.com/2019/04/whitepaper-life-sciences-409a-valuation-vs-valuation-to-raise-money/) - The US Internal Revenue Code has numerous regulations which must be adhered to in order for companies to reach compliance standards. One such regulation, Section 409A of the IRC, governs the complexities of setting strike prices for employee stock options and requires that companies be properly audited before issuing stock options as employee compensation. Often
- [Partnering and Investment – is the VC, Pharma, Biotech eco-system dead?](https://venturevaluation.com/2012/02/partnering-and-investment-is-the-vc-pharma-biotech-eco-system-dead/) - Partnering and Investment – is the VC, Pharma, Biotech eco-system dead? English (PDF) - 5 pages - 264kb
- [Site Selection for  Life Sciences  Companies 2013](https://venturevaluation.com/2013/10/selecting-a-european-location-for-life-sciences-activities/) - For Life Sciences companies it has never been easy selecting a location for HQs, shared services centers, manufacturing or R+D operations in Europe. A huge variety of factors must be taken into consideration. Venture Valuation, together with KPMG has analyzed the key decision factors relevant to site selection in Europe. Click here to read or
- [Biotechgate announces the launch of a clinical trial database](https://venturevaluation.com/2019/03/biotechgate-announces-the-launch-of-a-clinical-trial-database/) - Zurich, 25th March 2019 Biotechgate announces the launch of a clinical trial database with more than 460,000 trial records. Clinical trial data is imported from more than 13 registries around the world and continuously updated and catalogued. Thanks to the use of newly developed smart software components, the data is presented in a well-structured and
- [Whitepaper: Collaboration of Venture Valuation and Ferring Pharmaceuticals](https://venturevaluation.com/2019/03/white-paper-collaboration-of-venture-valuation-and-ferring-pharmaceuticals/) - Switzerland, March 2019: Venture Valuation has been working with Ferring Pharmaceutical supporting the company with external, third-party product/asset valuations of potential in-licensing opportunities. After Ferring had identified a specific opportunity and deemed interesting to move it forward in the internal evaluation process, Venture Valuation was mandated to review the product/opportunity from an external point of
- [Interviews with leading Life Sciences companies: Ava AG](https://venturevaluation.com/2019/03/interviews-with-leading-life-sciences-companies-ava-ag/) - Inspired by co-founder Lea von Bidder’s concept, the Ava bracelet is becoming an indispensable device for women to monitor their own biological rhythms. Venture Valuation (VV) interviewed Vicky Kummer, Global Brand Manager. Read the interview Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?
- [Venture Valuation Broschure](https://venturevaluation.com/2009/10/venture-valuation-broschure/) - Venture Valuation Broschure English (PDF) - 4 pages - 160kb
- [Whitepaper: Focus on the Antibiotics Market](https://venturevaluation.com/2017/07/whitepaper-focus-on-the-antibiotics-market/) - The antibiotics market is expected to reach USD 57.0 billion by 2024. Rising prevalence of infectious diseases is contributing to the market growth, especially in developing regions such as Asia-Pacific. However, raising capital for companies active in this field has been difficult for the past few years. Thus, Venture Valuation has collected some important facts,
- [Interviews with leading Life Sciences companies: Innophys Co.](https://venturevaluation.com/2019/01/interviews-with-leading-life-sciences-companies-innophys-co/) - Invented by Prof. Hiroshi Kobayashi, Department of Mechanical Engineering, Tokyo University of Science, the Muscle Suit® is becoming an indispensable device for the elderly care services as well as many other heavy lifting tasks. Venture Valuation (VV) interviewed Takashi Furukawa, CEO. Read the interview Would you like to be notified about new reports and other
- [VC Leman Club](https://venturevaluation.com/2001/10/vc-leman-club-2/) - VC Leman Club English (PDF) - 11 pages - 228kb
- [Interviews with leading Life Sciences companies: Cellestia Biotech AG](https://venturevaluation.com/2016/09/interviews-with-leading-life-sciences-companies-cellestia-biotech-ag/) - Created by two scientists at the École Politechnique Fédérale de Lausanne (EPFL) in 2014 and joined by experienced drug development and business professionals in 2015, Cellestia Biotech AG is developing oral medication along with companion diagnostics for Notch dependent hematological malignancies and solid tumors. Venture Valuation (VV) interviewed the CEO, Dr. Michael Bauer in Basel,
- [Interviews with leading Life Sciences companies: Sawai](https://venturevaluation.com/2010/07/interviews-with-leading-life-sciences-companies-sawai/) - Interviews with leading Life Sciences companies: Sawai English (PDF) - 4 pages - 182kb
- [Interviews with leading Life Sciences companies: Next Energy & Resouces Co. Ldt.](https://venturevaluation.com/2011/09/interviews-with-leading-life-sciences-companies-next-energy-resouces-co-ldt/) - Interviews with leading Life Sciences companies: Next Energy & Resouces Co. Ldt. English (PDF) - 3 pages - 791kb
- [Interviews with leading Life Sciences companies: Nakamura Brace Co.,Ltd.](https://venturevaluation.com/2013/09/interviews-with-leading-life-sciences-companies-nakamura-brace-co-ltd-2/) - Interviews with leading Life Sciences companies Nakamura Brace Co.,Ltd. Nakamura Brace Co Ltd - English - 4 pages - 258 kb
- [Interviews with leading Life Sciences companies: Sensimed](https://venturevaluation.com/2010/05/interviews-with-leading-life-sciences-companies-sensimed/) - Interviews with leading Life Sciences companies: Sensimed English (PDF) - 4 pages - 398kb
- [Interviews with leading Life Sciences companies: Mebiol Inc](https://venturevaluation.com/2011/04/interviews-with-leading-life-sciences-companies-mebiol-inc/) - Interviews with leading Life Sciences companies: Mebiol Inc English (PDF) - 4 pages - 331kb
- [Interviews with leading Life Sciences companies: AVA-CO2 Schweiz AG](https://venturevaluation.com/2012/02/interviews-with-leading-life-sciences-companies-ava-co2-schweiz-ag/) - Interviews with leading Life Sciences companies: AVA-CO2 Schweiz AG English (PDF) - 4 pages - 1001kb
- [Interviews with leading Life Sciences companies: Interprotein Corporation](https://venturevaluation.com/2012/03/interviews-with-leading-life-sciences-companies-interprotein-corporation/) - Interviews with leading Life Sciences companies: Interprotein Corporation English (PDF) – 3 pages – 680kb
- [Interviews with leading Life Sciences companies: Nakamura Brace Co.,Ltd. (Japanese)](https://venturevaluation.com/2013/10/interviews-with-leading-life-sciences-companies-nakamura-brace-co-ltd-japanese-language/) - Interviews with leading Life Sciences companies Nakamura Brace Co.,Ltd. Nakamura Brace Co Ltd – Japanese – 4 pages – 360 kb
- [Interviews with leading Life Sciences companies: Futaku Precision Machinery Industry Co.](https://venturevaluation.com/2014/06/interviews-with-leading-life-sciences-companies-futaku-precision-machinery-industry-co/) - Interviews with leading Life Sciences companies: Futaku Precision Machinery Industry Co. Futaku Precision Machinery Industry Co. - English - 3 pages - 1mb
- [Interviews with leading Life Sciences companies: Wastec, Inc.](https://venturevaluation.com/2014/09/interviews-with-leading-life-sciences-companies-wastec-inc/) - Interviews with leading Life Sciences companies: Wastec, Inc. Wastec, Inc. – English – 3 pages – 796kb
- [Interviews with leading Life Sciences companies: Abionic SA](https://venturevaluation.com/2015/11/interviews-with-leading-life-sciences-companies-abionic-sa/) - Pioneering research on biomolecular diffusion in nanofluidics, Abionic has developed the abioSCOPE, an in-vitro platform performing quantitative diagnostic testing. Its first application products: abioKIT Total IgE (1 test in 5min) and abioKIT Aeroallergens (6 tests in 12 min) are now available in the POC diagnostic market in Europe, and in 2016 in the U.S. Venture
- [Interviews with leading Life Sciences companies: CellSeed, Inc.](https://venturevaluation.com/2016/01/interviews-with-leading-life-sciences-companies-cellseed-mhi/) - Having leverage with its proprietary cell sheet engineering platform technology1, Cellseed is going to commercialize two products for which the regenerative medicine market has hardly waited. hardly waited for Venture Valuation (VV) interviewed the CEO, Dr. Setsuko Hashimoto Read the interview
- [Interviews with leading Life Sciences companies: Oncolys BioPharma Inc.](https://venturevaluation.com/2016/04/interviews-with-leading-life-sciences-companies-oncolys-biopharma-inc/) - Co-founded with Prof. Toshiyoshi Fujiwara1, the inventor of the telomerase specific oncolytic adenovirus technology, Oncolys BioPharma is committed to make its therapeutic and diagnostic products available for patients with intractable cancers. Venture Valuation (VV) interviewed Yasunari Kashihara, Vice President, Business Development, and Kohei Hata, Deputy Director, Corporate Development Read the interview
- [Interviews with leading Life Sciences companies: ObsEva SA](https://venturevaluation.com/2017/03/interviews-with-leading-life-sciences-companies-obseva-sa/) - ObsEva is specialized in re energizing women’s reproductive and pregnancy therapeutics that have been overlooked and underserved for years. Venture Valuation (VV) interviewed Dr. Ernest Loumaye, co-founder and CEO. Read the interview
- [Interviews with leading Life Sciences companies: GeNeuro SA](https://venturevaluation.com/2017/06/interviews-with-leading-life-sciences-companies-geneuro-sa/) - By leveraging expertise it has built up over decades in the HERV medical research and development, GeNeuro is engaging in unprecedented therapeutic development targeting HERVs. Venture Valuation (VV) interviewed Jesús Martin-Garcia, co-founder and CEO Read the interview.
- [Interviews with leading Life Sciences companies: PeptiDream Inc.](https://venturevaluation.com/2017/09/interviews-with-leading-life-sciences-companies-peptidream-inc/) - Inventiveness in peptide drug technology and a well thought- out business strategy characterize PeptiDream’s thriving growth. Venture Valuation (VV) interviewed Kiichi Kubota, co-founder and Chairman. Read the interview
- [Interviews with leading Life Sciences companies: tella inc.](https://venturevaluation.com/2018/02/interviews-with-leading-life-sciences-companies-tella-inc/) - Leveraging its proprietary technology of culturing highly purified dendritic cells (DCs), tella is developing, as its first immunotherapeutic product, a DC-based vaccine in combination with WT1 (Wilms’ tumor gene 1) antigen for inoperable pancreatic cancer. Venture Valuation (VV) interviewed Dr. Yuichiro Yazaki, President and CEO. Read the interview
- [Interviews with leading Life Sciences companies: Megakaryon Corporation](https://venturevaluation.com/2018/03/interviews-with-leading-life-sciences-companies-megakaryon-corporation/) - Current transfusion medicine entirely relies on donated blood. Megakaryon will change the transfusion practices by supplying safe and cost-saving platelets produced in vitro. Mass production in Japan is expected to begin in 2020. Venture Valuation (VV) interviewed Genjiro Miwa, CEO and Founder. Read the interview
- [Whitepaper: The Rise of Bigger, Earlier M&A Deals for Biotech](https://venturevaluation.com/2018/08/whitepaper-the-rise-of-bigger-earlier-ma-deals-for-biotech/) - Continuing a trend that began in 2017, this year has seen the rise of big investment deals in the biotech sector. Smaller biotechs are also cashing in as Big Pharma look to fill dwindling pipelines; according to Bloomberg data, biotech acquisitions are expected to be at the highest level for 12 years. Analysing this data from
- [Preview. Site Selection for Life Sciences Companies: Cluster Report 2015](https://venturevaluation.com/2015/02/cluster-report-2015/) - Venture Valuation presented a preview of its new report together with KPMG “Site Selection for Life Sciences Companies: Cluster Report 2015” in January at three locations including during JPMorgan in San Francisco, in Singapore and Taipei in February. The new report will be published in May 2015. For a copy of the key slides, please
- [Getting Real with Biotech Valuation](https://venturevaluation.com/2015/04/getting-real-with-biotech-valuation/) - This webinar provides insight into unique methods employed when valuing products and companies in Biotech. Speakers include Patrik Frei (Venture Valuation), David Thomas (BIO) et. al.
- [Biotechgate/Venture Valuation partners with Taiwan BIO](https://venturevaluation.com/2015/06/partners-with-taiwan-bio/) - Singapore / Taipei, June 2015 – Venture Valuation owned Biotechgate announces the partnership with Taiwan Bio Industry Organization to create a directory of Taiwanese Biotech companies. The database is the launch of a collaborative promotion of BIO Taiwan, one of the key Biotech and Life Sciences events in Asia. The Taiwanese Biotech Directory (www.taiwanesebiotech.com and
- [Life Sciences clusters in Europe Report 2016](https://venturevaluation.com/2016/06/life-sciences-clusters-in-europe-report-2016/) - Venture Valuation together with KPMG and EuropaBio has published its most recent report at BIO in San Francisco in June 2016. The data for the cluster analysis is from Biotechgate (www.biotechgate.com), the global Biotech and Life Sciences database. According to the report, there are three types of European countries attractive to locate key value drivers
- [How to value your startup](https://venturevaluation.com/2016/09/how-to-value-your-startup-4/) - RESI Conference, Boston September 2016, 36 pages How to value your startup
- [Valuation and HealthTech in Asia](https://venturevaluation.com/2017/01/valuation-and-healthtech-in-asia/) - RESI Conference, San Francisco January 2017, 23 pages Valuation and HealthTech in Asia, RESI (Jan 2017)
- [Site Selection Report for Life Sciences Companies in Europe 2018](https://venturevaluation.com/2018/07/site-selection-report-for-life-sciences-companies-in-europe-2018/) - The new Site Selection Report for Life Sciences Companies in Europe, compiled by KPMG in association with Venture Valuation, explores the when, where and how of successful European expansion. The publication looks beyond site selection to include key work streams involved in successfully commercializing pharmaceutical products in Europe. In the 2018 edition, we identify five
- [Biotechgate, HEALTH MADE IN GERMANY and Germany Trade & Invest (GTAI) to map German Life Science Industry](https://venturevaluation.com/2019/01/biotechgate-health-made-in-germany-and-germany-trade-invest-gtai-to-map-german-life-science-industry/) - Zurich/Berlin, January 2019; Venture Valuation entered into a partnership with HEALTH MADE IN GERMANY, the export promotion program for the German healthcare industry initiated by the German Federal Ministry for Economic Affairs and Energy. HEALTH MADE IN GERMANY is implemented by Germany Trade & Invest (GTAI), the country’s economic development agency. It is Venture Valuation’s
- [Life Sciences Clusters in Europe](https://venturevaluation.com/2015/11/life-sciences-clusters-in-europe/) - What makes a European Life Science site attractive to foreign investors? Together with KPMG Switzerland Venture Valuation has published this second edition statistic and extensive numbers on the European Biotechnology, Medical Technology and Pharma environment. The data is based on Biotechgate, the global Life Sciences database. Site Selection for Life Sciences Companies in Europe 2015:
- [Panel at JPM January 2017 – Future of Life Sciences](https://venturevaluation.com/2017/01/panel-at-jpm-january-2017-future-of-life-sciences/) - The topic if this year’s evening event at JPM in San Francisco co-organized by BaselArea.swiss Economic Promotion, KPMG and Venture Valuation was Designing The Future in Life Sciences - A Discussion About (Human) Capital & Innovation. How will life sciences look like in - let's say - 2030? What are sustainable and future business models for biotech
- [J.P. Morgan Healthcare Conference Round-up by Venture Valuation / Biotechgate](https://venturevaluation.com/2019/01/j-p-morgan-healthcare-conference-round-up-by-venture-valuation-biotechgate/) - 14 January 2019. Last week saw the annual J.P. Morgan Healthcare Conference held in San Francisco. Venture Valuation and Biotechgate was represented by CEO, Patrik Frei and Senior Business Development Executive Ray Carroll providing their insights into the industry announcements. It was again a busy week in San Francisco kicking off the Bio year 2019
- [Workshop - Deal and Product Valuations](https://venturevaluation.com/2019/02/workshop-deal-and-product-valuations/) - Paris, Gothenburg, Stockholm, Copenhagen, Barcelona, Feb 2019, 43 pages Workshop - Deal and Product Valuations
- [The Mandarin translation of Site Selection Report for Life Sciences Companies in Europe 2018](https://venturevaluation.com/2018/12/site-selection-report-for-life-sciences-companies-now-in-mandarin/) - Site Selection Report for Life Sciences Companies in Europe 2018 is now available in Mandarin and can be downloaded free by clicking at the link below: 生命科学企业在欧洲的选址（2018年版 The report, compiled by KPMG in association with Venture Valuation, explores the when, where and how of successful European expansion. The publication looks beyond site selection to include
- [Launch of a Directory of Life Sciences and Health Technologies companies with an exclusive database in Québec](https://venturevaluation.com/2018/11/launch-of-a-directory-of-life-sciences-and-health-technologies-companies-with-an-exclusive-database-in-quebec/) - Zurich / Montréal, November 26, 2018 As part of the ongoing commitment of Montréal InVivo to promote the economic development and growth of the life sciences and health technologies (LSHT) sector in Québec, Biotechgate, a company owned by Venture Valuation, and Montréal InVivo, the LSHT industrial cluster of the Montreal metropolitan area, announce a partnership
- [RESI Conference Sep 2018 – Deal and Product Valuations](https://venturevaluation.com/2018/09/resi-conference-sep-2018-deal-and-product-valuations/) - RESI Conference, Boston, Sep 2018, 36 pages Deal and Product Valuations Deal and Product Valuations
- [RESI Conference June 2018 – Deal and Product Valuations](https://venturevaluation.com/2018/06/resi-conference-june-2018-deal-and-product-valuations/) - RESI Conference, Boston, June 2018, 36 pages Deal and Product Valuations
- [How to value a Biotech Start-up company](https://venturevaluation.com/2018/05/how-to-value-a-biotech-start-up-company/) - Biotech Investment Showcase, London, May 2018, 22 pages How to value a Biotech Start-up company
- [RESI Conference January 2018 - Deal and Product Valuations](https://venturevaluation.com/2018/01/resi-conference-january-2018-deal-and-product-valuations/) - RESI Conference, San Francisco January 2018, 36 pages Deal and Product Valuations
- [RESI Conference April 2018 – Deal and Product Valuations](https://venturevaluation.com/2018/04/resi-conference-april-2018-deal-and-product-valuations/) - RESI Conference, Toronto, April 2018, 36 pages Deal and Product Valuations
- [The Launch of the BioAlberta Life Sciences Database](https://venturevaluation.com/2018/02/the-launch-of-the-albertan-life-sciences-database/) - Zurich, Edmonton January 2018 BioAlberta, a Canadian life sciences industry organization, has recently become a new business partner of Venture Valuation/Biotechgate. BioAlberta gathers a flourishing biotech community comprised of around 170 life sciences companies, government organizations, support service providers, and research & academic institutions, situated across the province. As per the partnership agreement, Venture Valuation
- [Industry Insight: Valuations](https://venturevaluation.com/2018/03/industry-insight-valuations/) - BIO-Europe Spring, Amsterdam March 2018, 12 pages Industry Insight: Valuations
- [Life Sciences BC - New Canadian Partner for Venture Valuation/Biotechgate](https://venturevaluation.com/2018/01/life-sciences-bc-new-canadian-partner-for-venture-valuationbiotechgate/) - Zurich/Vancouver January 2018 Biotechgate/Venture Valuation announce entering a partnership with Life Sciences British Columbia, a Canadian non-profit organization. The goal of the partnership is to develop and run a database comprised of the life science companies situated in the province of British Columbia. The database will be integrated into the Life Sciences BC website (lifesciencesbc.ca)
- [RESI Conference November 2017- Deal and Product Valuations](https://venturevaluation.com/2017/11/resi-conference-november-2017-deal-and-product-valuations/) - RESI Conference, New York November 2017, 37 pages Deal and Product Valuations
- [New Record in Valuation of Life Sciences Companies and Products](https://venturevaluation.com/2017/03/new-record-in-valuation-of-life-sciences-companies-and-products/) - Zurich / Singapore / Boston, March 2017 - Venture Valuation is looking back to a new record year in terms of valuations. The past year has seen a new record number of valuations provided by Venture Valuation to its clients with 45 valuations in 2016 compared to 31 in 2015. Over the two year period,
- [RESI Conference June 2017- Deal and Product Valuations Workshop](https://venturevaluation.com/2017/06/deal-and-product-valuations-june-2017/) - Dr. Patrik Frei, Venture Valuation CEO and a worldwide known expert in life sciences company and product valuation, delivered a workshop on the topic during he Redefining Early Stage Investments Conference in San Diego. The notes from the workshop are available to download here.
- [Venture Valuations Biotechgate Collaborates with California Life Sciences Association (CLSA) to Connect California’s Life Sciences Sector](https://venturevaluation.com/2017/08/venture-valuations-biotechgate-collaborates-with-clsa/) - Zurich, Bay Area & San Diego, CA – August 2017 – California Life Sciences Association (CLSA), the premier public policy advocacy and business leadership trade association representing California’s life sciences industry, and Venture Valuations Biotechgate, a global Life Sciences database today announced their collaboration to create an in-depth member directory for CLSA as well as a
- [Assessing the Valuation of New Ventures - MassChallengeCH, Lausanne, September 2017](https://venturevaluation.com/2017/09/assessing-the-valuation-of-new-ventures/) - Venture Valuation CEO, Dr. Patrik Frei is one of the experts working as mentors for MassChallengeCH, a famous startup accelerator. He helps new entrepreneurs understand the concepts and meaning of company valuation. Below, you can find a link to the notes from his workshop about assessing a company prior to valuation. Assessing the Valuation of New
- [Valuation Workshop at RESI Conference - Boston, September 2017](https://venturevaluation.com/2017/09/deal-and-product-valuations-sep-2017/) - During the last RESI (Redefining Early Stage Investments) Conference - the event series organized by Life Science Nation, a Venture Valuation long-time partner - Dr. Patrik Fried delivered a session on life science deal and product valuations. The notes from the workshop are available to download here
- [Story of the week at Venturix](https://venturevaluation.com/2001/06/story-of-the-week-at-venturix/) - Story of the week at Venturix by Patrik Frei English (PDF) - 2 pages - 28kb
- [Novartis Venture Fund](https://venturevaluation.com/1998/12/novartis-venture-fund/) - Novartis Venture Fund English (PDF) - 15 pages - 621kb
- [SWX Life Science Seminar](https://venturevaluation.com/2000/11/swx-life-science-seminar/) - SWX Life Science Seminar German (PDF) - 17 pages - 119kb
- [European Biotech Investment Forum](https://venturevaluation.com/2001/11/european-biotech-investment-forum/) - European Biotech Investment Forum English (PDF) - 18 pages - 305kb
- [How to approach the valuation of a biotech start-up company?](https://venturevaluation.com/2002/06/how-to-approach-the-valuation-of-a-biotech-start-up-company/) - How to approach the valuation of a biotech start-up company? By Hampus Hillerström French (PDF) - 7 pages - 656kb
- [Swiss Nanotech Roadshow (Boston, Chicago, San Jose)](https://venturevaluation.com/2002/05/swiss-nanotech-roadshow-boston-chicago-san-jose/) - Swiss Nanotech Roadshow (Boston, Chicago, San Jose) English (PDF) - 8 pages - 156kb
- [Melee Numerique Conference on IT and telecommunications (Toulouse, France)](https://venturevaluation.com/2002/06/melee-numerique-conference-on-it-and-telecommunications-toulouse-france/) - Melee Numerique Conference on IT and telecommunications (Toulouse, France) French (PDF) - 27 pages - 234kb
- [Reference letter of the Novartis Venture Fund](https://venturevaluation.com/1999/08/reference-letter-of-the-novartis-venture-fund/) - Reference letter of the Novartis Venture Fund English (PDF) - 1 pages - 36kb
- [Report on Venture Valuation published in BOOM 9/2001, November 2001](https://venturevaluation.com/2001/11/report-on-venture-valuation-published-in-boom-92001-november-2001/) - Report on Venture Valuation published in BOOM 9/2001, November 2001 German (PDF) - 2 pages - 110kb
- [Titlestory in Venture Capital/Going Public 3/2002, February 2002](https://venturevaluation.com/2002/02/titlestory-in-venture-capitalgoing-public-32002-february-2002/) - Titlestory in Venture Capital/Going Public 3/ February 2002 German (PDF) - 4 pages - 690kb
- [Article on Venture Valuation published in Bilanz, edition April 2002](https://venturevaluation.com/2002/04/article-on-venture-valuation-published-in-bilanz-edition-april-2002/) - Article on Venture Valuation published in Bilanz, edition April 2002 German (PDF) - 1 pages - 28kb
- [Press release in "Depeche du Midi" (Toulouse, France) mentioning Venture Valuation](https://venturevaluation.com/2002/06/press-release-in-depeche-du-midi-toulouse-france-mentioning-venture-valuation/) - Press release in "Depeche du Midi" (Toulouse, France) mentioning Venture Valuation French (PDF) - 1 pages - 209kb
- [IFJ-Apero](https://venturevaluation.com/2003/04/ifj-apero/) - IFJ-Apero German (PDF) - 38 pages - 325kb
- [Qualitative Beurteilung von Wachstumsunternehmen](https://venturevaluation.com/2003/03/qualitative-beurteilung-von-wachstumsunternehmen-patrik-frei-jost-renggli/) - Qualitative Beurteilung von Wachstumsunternehmen by Patrik Frei & Jost Renggli German (PDF) - 5 pages - 25kb
- [PSE - Parc Scientifique Lausanne](https://venturevaluation.com/2002/10/pse-parc-scientifique-lausanne/) - PSE - Parc Scientifique Lausanne French (PDF) - 43 pages - 598kb
- [Swiss Life Sciences Database at First Tuesday Zurich](https://venturevaluation.com/2003/03/swiss-life-sciences-database-at-first-tuesday-zurich/) - Swiss Life Sciences Database at First Tuesday Zurich English (PDF) - 12 pages - 460kb
- [First Swiss online life-science database launched](https://venturevaluation.com/2003/03/first-swiss-online-life-science-database-launched/) - First Swiss online life-science database launched English (PDF) - 1 pages - 7kb
- [Discounted-Cashflow-Methode](https://venturevaluation.com/2002/08/discounted-cashflow-methode-patrik-frei-jost-renggli/) - Discounted-Cashflow-Methode by Patrik Frei & Jost Renggli Winning Angles - Mentoren im Netzwerk des Erfolgs
- [BioContact](https://venturevaluation.com/2002/10/biocontact/) - BioContact English (PDF) - 13 pages - 386kb
- [Biotech Präsenzbörse Berlin](https://venturevaluation.com/2002/12/biotech-prasenzborse-berlin/) - Biotech Präsenzbörse Berlin German (PDF) - 13 pages - 512kb
- [IFZ-SECA-Seminar](https://venturevaluation.com/2003/06/ifz-seca-seminar/) - IFZ-SECA-Seminar English (PDF) - 6 pages - 334kb
- [Bewertungsmethoden](https://venturevaluation.com/2002/07/bewertungsmethoden/) - Bewertungsmethoden German (PDF) - 11 pages - 158kb
- [Brief summary of Japanese venture capital industry](https://venturevaluation.com/2002/08/brief-summary-of-japanese-venture-capital-industry-mika-kaneyuki/) - Brief summary of Japanese venture capital industry by Mika Kaneyuki English (PDF) - 5 pages - 17kb
- [Valuating the Company](https://venturevaluation.com/2003/07/valuating-the-company-patrik-frei-benoit-leleux/) - Valuating the Company by Patrik Frei & Benoît Leleux Starting a Business in the Life Sciences: From Idea to Market
- [First French Online Biotech Database Launched](https://venturevaluation.com/2004/03/first-french-online-biotech-database-launched/) - First French Online Biotech Database Launched English (PDF) - 1 pages - 60kb
- [Location: Switzerland Canada Road Show, Toronto](https://venturevaluation.com/2004/03/location-switzerland-canada-road-show-toronto/) - Location: Switzerland Canada Road Show, Toronto English (PDF) - 16 pages - 1192kb
- [MoT - Valuation of High-Tech Ventures, Lausanne](https://venturevaluation.com/2004/08/mot-valuation-of-high-tech-ventures-lausanne/) - MoT - Valuation of High-Tech Ventures, Lausanne English (PDF) - 7 pages - 345kb
- [Nature Biotechnology: Valuation - what you need to know](https://venturevaluation.com/2004/06/nature-biotechnology-valuation-what-you-need-to-know/) - Nature Biotechnology: Valuation - what you need to know by Patrik Frei & Benoît Leleux English (PDF) - 5 pages - 25kb
- [Qualitative Analysis of High-Growth Companies](https://venturevaluation.com/2004/11/qualitative-analysis-of-high-growth-companies/) - Qualitative Analysis of High-Growth Companies by Patrik Frei Englisch (PDF) - 1 Seiten - 144kb
- [Biotech International, London](https://venturevaluation.com/2003/11/biotech-international-london/) - Biotech International, London Biotech International, London
- [CTI - US Venture Day, Zurich](https://venturevaluation.com/2004/04/cti-us-venture-day-zurich/) - CTI - US Venture Day, Zurich English (PDF) - 11 pages - 505kb
- [BioContact, Quebec City](https://venturevaluation.com/2003/10/biocontact-quebec-city/) - BioContact, Quebec City English (PDF) - 7 pages - 505kb
- [Italian Biotech Database Launched](https://venturevaluation.com/2004/11/italian-biotech-database-launched/) - Italian Biotech Database Launched English (PDF) - 1 pages - 13kb
- [Venture Valuation strengthens Advisory Board](https://venturevaluation.com/2005/04/venture-valuation-strengthens-advisory-board/) - Venture Valuation strengthens Advisory Board English (PDF) - 2 pages - 65kb
- [Venture Valuation wins contract from European Investment Bank (EIB)](https://venturevaluation.com/2005/10/venture-valuation-wins-contract-from-european-investment-bank-eib/) - Venture Valuation wins contract from European Investment Bank (EIB) English (PDF) - 2 pages - 66kb
- [Swiss Biotechnology - Venture Capital, Johannesburg](https://venturevaluation.com/2005/10/swiss-biotechnology-venture-capital-johannesburg/) - Swiss Biotechnology - Venture Capital, Johannesburg English (PDF) - 22 pages - 1571kb
- [Seoul National University - "Valuation and the Biotechgate Database"](https://venturevaluation.com/2006/09/seoul-national-university-valuation-and-the-biotechgate-database/) - Seoul National University - "Valuation and the Biotechgate Database" English (PDF) - 36 pages - 953kb
- [Valuation and Investment in Biotech companies, Johannesburg](https://venturevaluation.com/2005/10/valuation-and-investment-in-biotech-companies-johannesburg/) - Valuation and Investment in Biotech companies, Johannesburg English (PDF) - 21 pages - 812kb
- [Swiss Life Sciences Sector, Johannesburg](https://venturevaluation.com/2005/10/swiss-life-sciences-sector-johannesburg/) - Swiss Life Sciences Sector, Johannesburg English (PDF) - 15 pages - 1520kb
- [1st China Partnering Event - "Venture Valuation / Chinese Biotech Database"](https://venturevaluation.com/2006/09/1st-china-partnering-event-venture-valuation-chinese-biotech-database/) - 1st China Partnering Event - "Venture Valuation / Chinese Biotech Database" English (PDF) - 13 pages - 561kb
- [IMD Lausanne - "Venture Valuaton CaseStudy - Valuation of high growth companies"](https://venturevaluation.com/2006/11/imd-lausanne-venture-valuaton-casestudy-valuation-of-high-growth-companies/) - IMD Lausanne - "Venture Valuaton CaseStudy - Valuation of high growth companies" English (PDF) - 33 pages - 598kb
- [Frühstück für Unternehmer - "Bewertung von Wachstumsfirmen"](https://venturevaluation.com/2007/02/fruhstuck-fur-unternehmer-bewertung-von-wachstumsfirmen/) - Frühstück für Unternehmer - "Bewertung von Wachstumsfirmen" German (PDF) - 10 pages - 331kb
- [Exit Strategies in Europe](https://venturevaluation.com/2006/10/exit-strategies-in-europe/) - Exit Strategies in Europe by Dr. Patrik Frei, Peter Buckel, Ulrich Dauer & Jean-Yves Nothias Englisch (PDF) - 3 Pages - 574kb
- [Assessment and Valuation of high growth companies](https://venturevaluation.com/2006/10/assessment-and-valuation-of-high-growth-companies/) - Assessment and Valuation of high growth companies (Swiss Private Equity & Corporate Finance Association) by Dr. Patrik Frei Available on Amazon.de
- [Valuation of Biopharmaceutical companies, Cologne](https://venturevaluation.com/2004/11/valuation-of-biopharmaceutical-companies-cologne/) - Valuation of Biopharmaceutical companies, Cologne English (PDF) - 13 pages - 195kb
- [Swiss Biotech and Medtech Day - "European Life Sciences Database"](https://venturevaluation.com/2005/01/swiss-biotech-and-medtech-day-european-life-sciences-database/) - Swiss Biotech and Medtech Day - "European Life Sciences Database" English (PDF) - 7 pages - 575kb
- [Assessment and valuation of technologies and high growth companies, Halifax](https://venturevaluation.com/2005/09/assessment-and-valuation-of-technologies-and-high-growth-companies-halifax/) - Assessment and valuation of technologies and high growth companies, Halifax English (PDF) - 16 pages - 208kb
- [Valuation of biotechnology companies](https://venturevaluation.com/2006/08/valuation-of-biotechnology-companies/) - Valuation of biotechnology companies by Dr. Patrik Frei Building Biotechnology: Starting, Managing, And Understanding Biotechnology Companies
- [IFJ-Apero - "Kriterien zur Start-up Finanzierung"](https://venturevaluation.com/2007/06/ifj-apero-kriterien-zur-start-up-finanzierung/) - IFJ-Apero - "Kriterien zur Start-up Finanzierung" German (PDF) - 37 pages - 196kb
- [BioValley Investors Lunch - "Valuation Principles](https://venturevaluation.com/2007/04/biovalley-investors-lunch-valuation-principles/) - BioValley Investors Lunch - "Valuation Principles BioValley Investors Lunch - "Valuation Principles
- [START Web 2.0, St. Gallen - "Valuation of high growth companies"](https://venturevaluation.com/2007/06/start-web-2-0-st-gallen-valuation-of-high-growth-companies/) - START Web 2.0, St. Gallen - "Valuation of high growth companies" English (PDF) - 23 pages - 929kb
- [Venture Valuation and BIOTECanada launch new online database of Canadian life sciences companies](https://venturevaluation.com/2007/04/venture-valuation-and-biotecanada-launch-new-online-database-of-canadian-life-sciences-companies/) - Venture Valuation and BIOTECanada launch new online database of Canadian life sciences companies English (PDF) - 1 pages - 20kb
- [Hochschulforum Herbst 2007, Zurich - "Kriterien und Bewertungsverfahren zur Start-up-Finanzierung"](https://venturevaluation.com/2007/10/hochschulforum-herbst-2007-zurich-kriterien-und-bewertungsverfahren-zur-start-up-finanzierung/) - Hochschulforum Herbst 2007, Zurich - "Kriterien und Bewertungsverfahren zur Start-up-Finanzierung" German (PDF) - 65 pages - 308kb
- [Business Tools, ETH Hoenggerberg, Zurich - "Exkurs: Unternehmensbewertung"](https://venturevaluation.com/2008/04/business-tools-eth-hoenggerberg-zurich-exkurs-unternehmensbewertung/) - Business Tools, ETH Hoenggerberg, Zurich - "Exkurs: Unternehmensbewertung" English (PDF) - 60 pages - 264kb
- [Messwerkzeuge des Business Analysten, Euroforum - Business Analyst 2008, Winterthur](https://venturevaluation.com/2008/09/messwerkzeuge-des-business-analysten-euroforum-business-analyst-2008-winterthur/) - Messwerkzeuge des Business Analysten, Euroforum - Business Analyst 2008, Winterthur German (PDF) - 22 pages - 147kb
- [Biotechgate and Naturejobs Collaboration to Aid Recruiters and Jobseekers Globally](https://venturevaluation.com/2007/12/biotechgate-and-naturejobs-collaboration-to-aid-recruiters-and-jobseekers-globally/) - Biotechgate and Naturejobs Collaboration to Aid Recruiters and Jobseekers Globally English (PDF) - 2 pages - 59kb
- [Venture Valuation launches 14 new databases that highlight the biotechnology activities in the new EU member states](https://venturevaluation.com/2008/11/venture-valuation-launches-14-new-databases-that-highlight-the-biotechnology-activities-in-the-new-eu-member-states/) - Venture Valuation launches 14 new databases that highlight the biotechnology activities in the new EU member states English (PDF) - 2 pages - 141kb
- [Biotech Industry and Valuation, Swissnex, Singapore](https://venturevaluation.com/2008/06/biotech-industry-and-valuation-swissnex-singapore/) - Biotech Industry and Valuation, Swissnex, Singapore English (PDF) - 28 pages - 964kb
- [International Biotech Clusters - a Global View, Regions and Location Guide](https://venturevaluation.com/2007/09/international-biotech-clusters-a-global-view-regions-and-location-guide/) - International Biotech Clusters - a Global View, Regions and Location Guide by Dr. Patrik Frei, Dr. Richard Munton English (PDF) - 2 pages - 249kb
- [Venture Valuation joins KAPPA-Health: a new project to help SMEs benefit from their participation in EU funded R&D projects](https://venturevaluation.com/2009/03/venture-valuation-joins-kappa-health-a-new-project-to-help-smes-benefit-from-their-participation-in-eu-funded-rd-projects/) - Venture Valuation joins KAPPA-Health: a new project to help SMEs benefit from their participation in EU funded R&D projects English (PDF) - 2 pages - 201kb
- [Biotech Day, Communication Forum – How to evaluate Biotech companies, Lugano](https://venturevaluation.com/2009/04/biotech-day-communication-forum-how-to-evaluate-biotech-companies-lugano/) - Biotech Day, Communication Forum – How to evaluate Biotech companies, Lugano English (PDF) - 18 pages - 744kb
- [The Swiss Pharma Biotech Landscape, ETHZ Career Event, Zurich](https://venturevaluation.com/2009/05/the-swiss-pharma-biotech-landscape-ethz-career-event-zurich/) - The Swiss Pharma Biotech Landscape, ETHZ Career Event, Zurich English (PDF) - 16 pages - 1775kb
- [Interview in Moneycap with Dr. Patrik Frei](https://venturevaluation.com/2009/04/interview-in-moneycap-with-dr-patrik-frei/) - Interview in Moneycap with Dr. Patrik Frei German (PDF) - 3 pages - 95kb
- [Maryland Biotechnology Center as new partner of Venture Valuations Biotechgate and USA Life Sciences Database](https://venturevaluation.com/2009/04/maryland-biotechnology-center-as-new-partner-of-venture-valuations-biotechgate-and-usa-life-sciences-database/) - Maryland Biotechnology Center as new partner of Venture Valuations Biotechgate and USA Life Sciences Database English (PDF) - 1 pages - 27kb
- [Interviews with leading Life Sciences companies: Japan Tissue Engineering Co., Ltd. (J-TEC)](https://venturevaluation.com/2009/03/interviews-with-leading-life-sciences-companies-japan-tissue-engineering-co-ltd-j-tec/) - Interviews with leading Life Sciences companies: Japan Tissue Engineering Co., Ltd. (J-TEC) English (PDF) - 2 pages - 239kb
- [Interviews with leading Life Sciences companies: Institute of Medicinal Molecular Design, Inc. (IMMD)](https://venturevaluation.com/2009/03/interviews-with-leading-life-sciences-companies-institute-of-medicinal-molecular-design-inc-immd/) - Interviews with leading Life Sciences companies: Institute of Medicinal Molecular Design, Inc. (IMMD) English (PDF) - 2 pages - 153kb
- [Interviews with leading Life Sciences companies: SBI Biotech Co., Ltd. (SBIBT)](https://venturevaluation.com/2009/03/interviews-with-leading-life-sciences-companies-sbi-biotech-co-ltd-sbibt/) - Interviews with leading Life Sciences companies: SBI Biotech Co., Ltd. (SBIBT) English (PDF) - 2 pages - 212kb
- [Interviews with leading Life Sciences companies: MediciNova, Inc.](https://venturevaluation.com/2009/04/interviews-with-leading-life-sciences-companies-medicinova-inc/) - Interviews with leading Life Sciences companies: MediciNova, Inc. English (PDF) - 2 pages - 187kb
- [Interviews with leading Life Sciences companies: Carna Bioscience](https://venturevaluation.com/2009/04/interviews-with-leading-life-sciences-companies-carna-bioscience/) - Interviews with leading Life Sciences companies: Carna Bioscience English (PDF) - 2 pages - 262kb
- [Biotech Funding Trends: Dr. Alexandra Gruber](https://venturevaluation.com/2009/04/biotech-funding-trends-dr-alexandra-gruber/) - Biotech Funding Trends: Dr. Alexandra Gruber English (PDF) - 1 pages - 24kb
- [Interviews with leading Life Sciences companies: NanoCarrier](https://venturevaluation.com/2009/05/interviews-with-leading-life-sciences-companies-nanocarrier/) - Interviews with leading Life Sciences companies: NanoCarrier English (PDF) - 3 pages - 226kb
- [Interviews with leading Life Sciences companies: JCAM](https://venturevaluation.com/2009/05/interviews-with-leading-life-sciences-companies-jcam/) - Interviews with leading Life Sciences companies: JCAM English (PDF) - 3 pages - 184kb
- [Bilan: 20 most influential people in the Swiss Life Sciences Industry](https://venturevaluation.com/2009/05/bilan-20-most-influential-people-in-the-swiss-life-sciences-industry/) - Bilan: 20 most influential people in the Swiss Life Sciences Industry French (PDF) - 8 pages - 125kb
- [Interviews with leading Life Sciences companies: Kringle Pharma](https://venturevaluation.com/2009/07/interviews-with-leading-life-sciences-companies-kringle-pharma/) - Interviews with leading Life Sciences companies: Kringle Pharma English (PDF) - 3 pages - 251kb
- [Interviews with leading Life Sciences companies: Anaeropharma Science](https://venturevaluation.com/2009/07/interviews-with-leading-life-sciences-companies-anaeropharma-science/) - Interviews with leading Life Sciences companies: Anaeropharma Science English (PDF) - 3 pages - 256kb
- [Wie sich Startups bewerten lassen](https://venturevaluation.com/2010/06/wie-sich-startups-bewerten-lassen/) - Wie sich Startups bewerten lassen by Jost Renggli Article on wirtschaft.ch
- [Private funding: Find right investor - do’s and dont’s in fund raising, Biotech Forum, Stockholm](https://venturevaluation.com/2009/11/private-funding-find-right-investor-dos-and-donts-in-fund-raising-biotech-forum-stockholm/) - Private funding: Find right investor - do’s and dont’s in fund raising, Biotech Forum, Stockholm English (PDF) - 19 pages - 394kb
- [Licensing deal versus VC financing: A valuation approach, Swiss Pharma Licensing Group, Flims](https://venturevaluation.com/2010/01/licensing-deal-versus-vc-financing-a-valuation-approach-swiss-pharma-licensing-group-flims/) - Licensing deal versus VC financing: A valuation approach, Swiss Pharma Licensing Group, Flims English (PDF) - 20 pages - 521kb
- [Valuation of Biotech Companies and Technology - BioKorea 2010, Seoul](https://venturevaluation.com/2010/09/valuation-of-biotech-companies-and-technology-biokorea-2010-seoul/) - Valuation of Biotech Companies and Technology - BioKorea 2010, Seoul English (PDF) - 27 pages - 472kb
- [Biotech in the new EU member states report released](https://venturevaluation.com/2009/11/biotech-in-the-new-eu-member-states-report-released/) - Biotech in the new EU member states report released English (PDF) - 2 pages - 331kb
- [Fairness opinion for the reverse merger of Arpida and Evolva](https://venturevaluation.com/2009/12/fairness-opinion-for-the-reverse-merger-of-arpida-and-evolva/) - Fairness opinion for the reverse merger of Arpida and Evolva English (PDF) - 1 pages - 17kb
- [What Can Polish Biotechnology Offer Western Industry](https://venturevaluation.com/2010/06/what-can-polish-biotechnology-offer-western-industry/) - What Can Polish Biotechnology Offer Western Industry English(PDF) - 16 pages - 642kb
- [Interviews with leading Life Sciences companies: Nanoegg](https://venturevaluation.com/2009/08/interviews-with-leading-life-sciences-companies-nanoegg/) - Interviews with leading Life Sciences companies: Nanoegg English (PDF) - 4 pages - 279kb
- [Interviews with leading Life Sciences companies: Watervein Partners](https://venturevaluation.com/2009/10/interviews-with-leading-life-sciences-companies-watervein-partners/) - Interviews with leading Life Sciences companies: Watervein Partners English (PDF) - 3 pages - 209kb
- [Interviews with leading Life Sciences companies: ArBlast Co.](https://venturevaluation.com/2009/10/interviews-with-leading-life-sciences-companies-arblast-co/) - Interviews with leading Life Sciences companies: ArBlast Co. English (PDF) - 3 pages - 182kb
- [Interviews with leading Life Sciences companies: Interprotein](https://venturevaluation.com/2009/11/interviews-with-leading-life-sciences-companies-interprotein/) - Interviews with leading Life Sciences companies: Interprotein English (PDF) - 4 pages - 217kb
- [Interviews with leading Life Sciences companies: POC Clinical Research](https://venturevaluation.com/2010/01/interviews-with-leading-life-sciences-companies-poc-clinical-research/) - Interviews with leading Life Sciences companies: POC Clinical Research English (PDF) - 3 pages - 218kb
- [Interviews with leading Life Sciences companies: Linical](https://venturevaluation.com/2010/01/interviews-with-leading-life-sciences-companies-linical/) - Interviews with leading Life Sciences companies: Linical English (PDF) - 3 pages - 163kb
- [Interviews with leading Life Sciences companies: GenKyoTex](https://venturevaluation.com/2010/02/interviews-with-leading-life-sciences-companies-genkyotex/) - Interviews with leading Life Sciences companies: GenKyoTex English (PDF) - 4 pages - 268kb
- [Launch Academic Database at Biotechnica, Hannover](https://venturevaluation.com/2010/10/launch-academic-database-at-biotechnica-hannover/) - Launch Academic Database at Biotechnica, Hannover English (PDF) - 24 pages - 954kb
- [Deal-making in the Antibody Space](https://venturevaluation.com/2011/06/deal-making-in-the-antibody-space/) - More than 150 antibody products and technologies will be offered for partnering at the BIO International convention later this month. Since knowledge of historical deal information is a crucial prerequisite for deal negotiation, we have examined over 150 therapeutic antibody deals listed in the Biotechgate Licensing Deals database to compile this detailed analysis as well
- [Biotechgate welcomes two new partners in France and Italy](https://venturevaluation.com/2011/02/biotechgate-welcomes-two-new-partners-in-france-and-italy/) - Biotechgate welcomes two new partners in France and Italy English (PDF) - 2 pages - 25kb
- [One Nucleus signs agreement with Venture Valuation to enable dealflow](https://venturevaluation.com/2011/03/one-nucleus-signs-agreement-with-venture-valuation-to-enable-dealflow/) - One Nucleus signs agreement with Venture Valuation to enable dealflow English (PDF) - 2 pages - 165kb
- [Over 20’000 Company Profiles now available in the new Version of Biotechgate](https://venturevaluation.com/2011/03/over-20000-company-profiles-now-available-in-the-new-version-of-biotechgate/) - ZURICH, March 2011 – Biotechgate has launched a new version of its Global Biotechgate Database with new search features and state-of the art usability. At the same time the database has reached over 20’000 company profiles. The new version of Biotechgate, the global Biotech and Life Sciences Database, provides the user with a new interface
- [Keeping up with the Biotech industry](https://venturevaluation.com/2011/06/keeping-up-with-the-biotech-industry-2/) - Real time access to the dynamic data used to generate reports is a clear advantage allowing you to see trends as they develop instead of being limited to a snapshot view of one point in time. Read this article to learn how you can access the information behind the statistics reports in real-time. By Jost
- [BIO 2011: Deal-making in the Antibody Space](https://venturevaluation.com/2011/06/bio-2011-deal-making-in-the-antibody-space-2/) - BIO 2011: Deal-making in the Antibody Space English (PDF) - 2 pages - 200kb
- [VC Deal Summary June 2011](https://venturevaluation.com/2011/06/vc-deal-summary-june-2011-2/) - VC Deal Summary June 2011 Englisch (PDF) - 10 Seiten - 1461kb
- [VC Deal Summary August 2011](https://venturevaluation.com/2011/09/vc-deal-summary-august-2011-3/) - VC Deal Summary August 2011 English (PDF) - 12 Pages - 327kb
- [Top Value drivers in the Life Science Industry](https://venturevaluation.com/2011/09/top-value-drivers-in-the-life-science-industry-2/) - Top Value drivers in the Life Science Industry English (PDF) - 4 Pages - 89kb
- [BIO-Europe 2011: Early Stage Oncology Deals](https://venturevaluation.com/2011/10/bioeurope-2011-early-stage-oncology-deals/) - BIO-Europe 2011: Early Stage Oncology Deals English (PDF) - 2 pages 192kb
- [Comparison of early stage funding in the US and EU – who gets more money?](https://venturevaluation.com/2012/01/comparison-of-early-stage-funding-in-the-us-and-eu-who-gets-more-money/) - Comparison of early stage funding in the US and EU – who gets more money? English (PDF) – 3 pages 172kb
- [Biotech Cluster Bay Area and Switzerland – a Comparison](https://venturevaluation.com/2012/01/biotech-cluster-bay-area-and-switzerland-a-comparison/) - Biotech Cluster Bay Area and Switzerland – a Comparison English (PDF) – 3 pages 116kb
- [Where does big pharma take the new drug discovery from?](https://venturevaluation.com/2012/02/where-does-big-pharma-take-the-new-drug-discovery-from/) - Where does big pharma take the new drug discovery from? English (PDF) - 2 pages 339kb
- [Wieviel ist mein Unternehmen Wert? Start Impuls Apéro, Chur](https://venturevaluation.com/2012/04/wieviel-ist-mein-unternehmen-wert-venture-apero-frauenfeld/) - Wieviel ist mein Unternehmen Wert? Start Impuls Apéro, Chur German (PDF) – 39 pages 680kb
- [Public Biotechs – Light at the end of the tunnel, although private Biotechs may have to wait a bit longer](https://venturevaluation.com/2012/03/public-biotechs/) - Amsterdam March 2012: An overview of the state of the Biotech Industry was given by BIOs Industry Research & Analyst David Thomas at BIOEuropeSpring in Amsterdam. He made three main points: Public market have gained 25% in the last couple of month Private Biotechs still have a hard time to find investors Partnering and deal making
- [How big Pharma companies structure their licensing deals – prepare for BIO 2012](https://venturevaluation.com/2012/05/how-big-pharma-companies-structure-their-licensing-deals-prepare-for-bio-2012/) - Most companies dream about closing a licensing deal with big Pharma. But what do these deals really contain from a financial perspective and can any trends be found for potential big Pharma licensees in order to assist licensors in the deal making process? To gain insight in these aspects, we have analyzed the financial deal
- [London/Cambridge and Zurich: A comparison in numbers, London](https://venturevaluation.com/2012/08/londoncambridge-and-zurich-a-comparison-in-numbers-london/) - London/Cambridge and Zurich: A comparison in numbers, London English (PDF) - 14 Pages 648kb
- [Singapore The Business Times, Growing business opportunities](https://venturevaluation.com/2012/08/singapore-the-business-times-growing-business-opportunities/) - Singapore The Business Times, Growing business opportunities (page 6) English (PDF) - 15 Pages 8799kb
- [Swiss-Scandinavian Bio-Business Seminar](https://venturevaluation.com/2012/08/swiss-scandinavian-bio-business-seminar/) - English (PDF) - 2 Pages 290kb
- [Funding for Life Sciences - how, when and where to get money from, Brazil (incl. Audio)](https://venturevaluation.com/2012/08/funding-for-life-sciences-how-when-and-where-to-get-money-from-brazil-incl-audio/) - English (PPT) - 28 Pages 9607kb
- [Public versus private funding opportunities for life sciences, Meet4Lifescience, Basel](https://venturevaluation.com/2012/08/public-versus-private-funding-opportunities-for-life-sciences-meet4lifescience-basel/) - English (PDF) - 28 Pages 496kb
- [London-Cambridge, UK and Canada Biotech comparison, London](https://venturevaluation.com/2012/12/london-cambridge-uk-and-canada-biotech-comparison-london/) - English (PDF) - 17 Pages 1225kb
- [Biotechgate continues to improve company profile tracking with new ‘save search’ functionality](https://venturevaluation.com/2013/02/biotechgate-save-search/) - To enable users to track company profiles of interest, Biotechgate have recently rolled out a new feature allowing Biotechgate users to be notified by email when a set company profile has been changed in any way. Biotechgate`s life science database has continued to grow to over 25,700 company profiles. The wealth of information includes concise
- [Biotechgate's (BTG) Country Profile  - Switzerland](https://venturevaluation.com/2013/03/biotechgates-btg-country-profile-switzerland/) - Biotechgate's (BTG) Country Profile (PDF) - 3 Pages 556kb
- [Canada - comparison in numbers, April 2013, BIO Chicago](https://venturevaluation.com/2013/04/canada-april-2013/) - Canada - comparison in numbers, April 2013, BIO Chicago English (PDF) - 12 pages - 957kb
- [Celebrating 10 years of Biotechgate](https://venturevaluation.com/2013/04/celebrating-10-years-of-biotechgate/) - Media Release ZURICH, April 2013: Biotechgate is celebrating its 10 year anniversary this year. With over 28’000 company profiles, 6000 licensing opportunities, 1500 deals and over 30 partners worldwide, it represents the largest online life sciences database of its kind. Ten years ago, Venture Valuation started with its first database in Switzerland. At the time,
- [Asian expansion – Venture Valuation is taking advantage of growth in Asia opening a new office in Singapore](https://venturevaluation.com/2013/12/asian-expansion-venture-valuation-is-taking-advantage-of-growth-in-asia-opening-a-new-office-in-singapore/) - Asian expansion – Venture Valuation is taking advantage of growth in Asia opening a new office in Singapore ZURICH / SINGAPORE, December 2013 – Venture Valuation has recently opened its Asian office in Singapore to take advantage of the growing life sciences sector in Asia and to be even closer to its customers. Having had
- [How do you determine the discount rate you need to calculate the current value of a company that hasn’t generated revenues yet?](https://venturevaluation.com/2014/01/how-do-you-determine-the-discount-rate-you-need-to-calculate-the-current-value-of-a-company-that-hasnt-generated-revenues-yet/) - The meaning of a “discount rate” is best understood by making a parallel with the interest rate you get from the bank on your savings account. While the interest rate is a % you use to calculate what 100 USD or EUR on your account will become after a number of years, the discount rate
- [Global, Early-Stage Investors in Emerging Life Science Companies](https://venturevaluation.com/2014/02/global-early-stage-investors-in-emerging-life-science-companies/) - Does it make sense for a life science fundraising executive in Europe to look internationally for early-stage funding? Should U.S. based firms look at investors in Europe and Asia? As the famous folk singer Bob Dylan sang “the times they are a changing” and the answer is yes! To someone looking to fund a
- [Licensing demand for biotech products will increase](https://venturevaluation.com/2014/02/licensing-demand-for-biotech-products-will-increase/) - The recent acquisition of Forest Laboratories Inc. by Actavis for USD 25bn shows the trend of generic producers to move into the innovative drug space. With fewer blockbusters on the market, companies focused on generics will need to move into innovative therapeutics. The acquisition of Forest Laboratories Inc. by Actavis is a clear sign where
- [How to value your startup?](https://venturevaluation.com/2014/03/how-to-value-your-startup/) - Presentation at RESI conference, March 2014 Click here to download the presentation (PDF) - 36 pages - 507kb
- [Early stage VC funding in the US more difficult than ever](https://venturevaluation.com/2014/03/early-stage-vc-funding-in-the-us-more-difficult-than-ever/) - Even with the public biotech was just at an all time high, VCs in the US also have difficulties convincing LPs (Limited Partners) to make investment in their funds. At a recent panel discussion led by Venture Valuation at the RESI (redefining early stage investment) conference in Boston, VCs offered an insight into their perspective
- [Wieviel ist mein Unternehmen Wert? Praktische Tipps zur Bewertung von Startups](https://venturevaluation.com/2014/04/wieviel-ist-mein-unternehmen-wert-praktische-tipps-zur-bewertung-von-startups/) - Presentation at Technopark Luzern, April 22nd 2014 Click here to download the presentation (PDF) - 35 pages - 607kb
- [What is the impact of Novartis transformation on biotech industry?](https://venturevaluation.com/2014/04/what-is-the-impact-of-novartis-transformation-on-biotech-industry/) - With the announcement of the portfolio transformation of Novartis this month, we believe this will have a positive impact on the biotech industry. The company will focus on Pharmaceuticals, Eye Care and Generics. The diversification strategy of former CEO and Chairman Daniel Vasella has been axed by the new leadership of Novartis. Key components of
- [Who is investing and who is not?](https://venturevaluation.com/2014/04/who-is-investing-and-who-is-not/) - Are you wondering what investors still have money and are investing? At Biotechgate we are tracking all financing of investors and we also run a global database of what investors are looking for. As an example, the following investors have made investments into European Health Care companies in Q1 2014: AT NewTec, Germany Boehringer Ingelheim
- [European Biotech  Pharma Innovation Development - Chinese Version](https://venturevaluation.com/2014/05/european-biotech-pharma-innovation-development-chinese-version/) - European Biotech Pharma Innovation Development - Chinese Version, Sino-Euro BioPartnering Forum, Shanghai, May 2014, 15 pages, 1180 kb
- [European Biotech  Pharma Innovation Development - English Version](https://venturevaluation.com/2014/05/european-biotech-pharma-innovation-development-english-version/) - European Biotech Pharma Innovation Development - English Version, Sino-Euro BioPartnering Forum, Shanghai, May 2014, 15 pages, 980 kb
- [Is Orphan saving Biotech?](https://venturevaluation.com/2014/05/is-orphan-saving-biotech/) - Orphan drugs have been en vogue for a while. However, in the last quarter there has been a record financing that has put drugs for small patient populations on the map even more. In Q1 2014, over 60% of the financing in European Biotech has gone to companies that have a lead orphan drug product.
- [What you need to know to succeed in doing deals and financing](https://venturevaluation.com/2014/05/what-you-need-to-know-to-succeed-in-doing-deals-and-financing/) - What you need to know to succeed in doing deals and financing, BioKorea, Seoul, May 2014, 32 pages, 871 kb
- [Overview of European Biotech & Pharma](https://venturevaluation.com/2014/05/overview-of-european-biotech-pharma/) - Overview of European Biotech & Pharma, Tokyo, May 2014, 28 pages, 1390 kb
- [Investment trends and opportunities in drug discovery and development](https://venturevaluation.com/2014/06/investment-trends-and-opportunities-in-drug-discovery-and-development/) - Investment trends and opportunities in drug discovery and development, Hong Kong, June 2014, 17 pages, 858kb
- [Soccer and Pharma/BIOtech](https://venturevaluation.com/2014/06/soccer-and-pharmabiotech/) - Marketing alliances between well-known brand names and consumer products have long been a tradition for example Michael Jackson and Pepsi or George Clooney and Nespresso. Soccer clubs are also dependent on sponsor income and are working with many different industries like telecoms, airlines and insurances. Now prestigious Manchester United (Man U) has signed a marketing
- [The premium of a big pharma license deal](https://venturevaluation.com/2014/07/the-premium-of-a-big-pharma-license-deal/) - Venture Valuation recently published an article in Nature Biotechnology 32, 617–619, (2014) based on data from its Biotechgate deals database looking at the difference between big pharma and SMEs in the upfront payments and number of deals. Read more here (Nature Biotechnology) To get access to Biotechgate, please contact us here. Source: Nature Biotechnology, 32,
- [HTX, BiotechGate and partners produce the first, comprehensive Canadian Medtech Ecosystem Database.](https://venturevaluation.com/2014/08/htx-biotechgate-and-partners-produce-the-first-comprehensive-canadian-medtech-ecosystem-database/) - Toronto, August 2014 An HTX led consortium, recently partnered with Biotechgate in launching a Canadian medtech sector specific database. Access to accurate data on the Canadian medtech sector along with other industry statistics is critical for aligning innovation and with key partners during various stages of product development and adoption. Over 20 medtech databases have
- [European Medical Technology Innovation Development - Chinese Version](https://venturevaluation.com/2014/09/european-medical-technology-innovation-development-chinese-version/) - Chinese Version, China Medtech Partnering CMP 2014, Suzhou, September 2014, 14 pages, 1'000kb
- [European Medical Technology Innovation Development - English Version](https://venturevaluation.com/2014/09/european-medical-technology-innovation-development-english-version/) - English Version, China Medtech Partnering CMP 2014, Suzhou, September 2014, 14 pages, 969kb
- [New Investor Database launched](https://venturevaluation.com/2014/09/new-investor-database-launched/) - Venture Valuation owned Biotechgate announces the launch of a new investor database. The goal of the new directory is to make the fundraising process for capital raising companies more effective and efficient. Click here to read the press release >>
- [Comparison of European Life Sciences Clusters](https://venturevaluation.com/2014/09/comparison-of-european-life-sciences-clusters/) - Regionenvergleich: Life Sciences in Europa (German), Zurich, August 2014, 20 pages, 1340kb
- [How to raise sufficient funds for Biotechs?](https://venturevaluation.com/2014/09/how-to-raise-sufficient-funds-for-european-biotech/) - September 2014: Financing is an ongoing challenge for all Biotech companies. Without sufficient resources, products cannot be advanced in the development. Scarce resources help companies to focus as it is more important to bring one or two products into the clinic than advancing five different programs in pre-clinical development. But many European companies are struggling
- [What is Value for Investors](https://venturevaluation.com/2014/10/what-is-value-for-investors/) - ScanBalt Forum, Groningen October 2014 – English version, 35 pages, 2,55mb
- [Biotechgate partners with HollandBIO to launch a Biotech directory for the Netherlands](https://venturevaluation.com/2014/10/biotechgate-partners-with-hollandbio-to-launch-a-biotech-directory-for-the-netherlands/) - Switzerland /The Netherlands, Oct 2014 – Venture Valuation owned Biotechgate announces the partnership with HollandBIO to create a directory of Dutch Biotech, Pharma and Medtech companies. In addition the platform is supported by Medical Delta, the life sciences and medical technology cluster in the west of the Netherlands. The online directory makes it easier to
- [Biotechgate welcomes three new partners in Norway to further complete the Nordic Life Science Database](https://venturevaluation.com/2014/11/norwegian-partnership/) - Switzerland /Norway, November 2014 – Biotechgate welcomes the three Norwegian partners Innovation Norway, Oslo Cancer Cluster and Nansen Neuroscience Network. This partnership further completes the Nordic Life Sciences Database which allows users to search for companies in the Biotech, Pharma and Medtech area. More than 170 Norwegian companies can currently be found in the Nordic
- [Biotechgate expands to Finland: We welcome our new partner, Turku Science Park](https://venturevaluation.com/2015/03/biotechgate-expands-to-finland/) - Switzerland / Finland, February 2015 – As a result of the partnership with Turku Science Park Ltd, Biotechgate gained its first partner in Finland. This partnership closes an important gap in the Nordic Life Science Database. Turku Science Park (Finland) is now an official partner of Biotechgate and the Nordic Life Science Database. Thanks to
- [Creativity in Deal Making](https://venturevaluation.com/2015/05/creativity-in-deal-making/) - Swiss & Italian HLG Summer Conference, Lugano Switzerland, May 2015, English, 20 pages, 663kb
- [Pharma-Biotech Financing](https://venturevaluation.com/2015/05/pharma-biotech-financing/) - Fit for Health 2.0, Palermo Italy, May 2015, English, 35 pages, 1.05 MB
- [Identifying the Best Investment Model and Valuating Biosimilar Opportunities](https://venturevaluation.com/2015/05/biosimilars-investment/) - Biosimilars Investment Model and Opportunities, Asia, May 2015, 22 pages, 877kb
- [MedTech Investment Landscape](https://venturevaluation.com/2015/07/medtech-investment-landscape/) - Even though the number of medical technology companies in North America, Europe and Asia are not so different, the investment landscape is very much so. See the actual numbers in a recent presentation of Venture Valuation in Singapore. Medtech Connect, Singapore, July 2014, 9 pages, 512kb
- [Webinar on clinical trials for Horizon 2020 projects](https://venturevaluation.com/2015/08/webinar-on-clinical-trials-for-horizon-2020-projects/) - This miniclip, organized by Fit for Health 2.0 (http://www.fitforhealth.eu/), presents definitions and resources for registration and design of clinical trials in the EU. The presentation includes an introduction to the procedure to get clinical trials funded in Horizon 2020. Mini-Clip PDF Presentation, 11, 464kB Mini-Clip
- [How to value your startup](https://venturevaluation.com/2015/09/how-to-value-your-startup-2/) - Presentation at RESI conference, September 2015: How to value your startup, RESI (Sep 2015)
- [VALUING YOUR OPPORTUNITY – How industry and investors evaluate your project or company](https://venturevaluation.com/2015/09/valuing-your-opportunity-how-industry-and-investors-evaluate-your-project-or-company/) - How to value your startup, TTS (Sep 2015): TechTransfer Summit TTS, Brisbane, Australia, September 2015, 34 pages, 1’014kb
- [Valuation of Biosimilar and Key value Drivers](https://venturevaluation.com/2015/11/valuation-of-biosimilar-and-key-value-drivers/) - Biosimilar Asia Pacific, Singapore, October 2015, 24 pages
- [European Life Sciences Report - Site Selection for Life Sciences Companies](https://venturevaluation.com/2015/11/european-life-sciences-report-site-selection-for-life-sciences-companies/) - Zurich / Singapore, November 2015 - Venture Valuation together with KPMG has released its 2015 Report on “Site Selection for Life Sciences companies in Europe”. The report looks across the European Life Sciences landscape, analysing and comparing 14 European countries. The report looks at the strength of Biotechnology, Medical Technology and Pharma. This second edition
- [Biotechgate down-under - New life sciences directory for Australia](https://venturevaluation.com/2015/11/biotechgate-down-under-new-life-sciences-directory-for-australia/) - Zurich / Melbourne, November 2015: Venture Valuations Biotechgate and AusBiotech, the Australian Biotech Industry Association, have entered into an agreement to create a comprehensive directory of Australian biotechnology and life science companies and extend the network and reach of Biotechgate. The Australian Life Sciences Directory will have a standalone web address and will also be
- [How strong is the London-Cambridge cluster within the UK?](https://venturevaluation.com/2015/12/how-strong-is-the-london-cambridge-cluster-within-the-uk/) - See our exclusive 2015 analysis we did for the Genesis conference (organized by our partner Onenucleus). Download cluster report »
- [How to value your startup](https://venturevaluation.com/2016/01/how-to-value-your-startup-3/) - RESI Conference, San Francisco January 2016, 37 pages How to value your startup
- [Biotechgate enters collaboration with Nasdaq GlobeNewswire](https://venturevaluation.com/2016/02/biotechgate-enters-collaboration-with-nasdaq-globenewswire/) - Biotechgate, owned by Venture Valuation has partnered with Nasdaq GlobeNewswire to distribute Nasdaq’s GlobeNewswire press releases on Biotechgate and all its related country portals. Through the collaboration, Biotechgate will provide Nasdaq GlobeNewswire with an additional worldwide and focused publication channel. Biotechgate will publish the Biotech and life science related news on its website www.biotechgate.com and
- [Life Sciences in Europe Report - Smart Site Selection](https://venturevaluation.com/2016/06/life-sciences-in-europe-report-smart-site-selection/) - Zurich / Singapore, June 2016 - Venture Valuation together with KPMG and its new partner EuropaBio has released its third Report on “Site Selection for Life Sciences companies in Europe”. The report now also added additional countries including Denmark, Finland, Italy, Spain and Sweden. The report looks at the strength of Biotechnology, Medical Technology and

## Pages

- [Home](https://venturevaluation.com/) - We specializes in independent assessments and valuations of companies/products in biotech/life sciences and runs the business development database Biotechgate with global licensing deals and opportunities www.biotechgate.com and Biotechgate Digital Partnering www.digitalpartnering.com
- [Workshops](https://venturevaluation.com/workshops/) - Venture Valuation offers several industry-focused workshops on relevant topics such as valuation and financing.
- [Company & History](https://venturevaluation.com/company-history/) - Venture Valuation was founded in 1999 based on profound research work by the founder and CEO, Dr. Patrik Frei, at the University of St. Gallen (HSG) and the Swiss Federal Institute of Technology in Lausanne (EPFL). The company has remained true to its mission: the independent assessment and valuation of companies, products and assets.
- [Our Clients](https://venturevaluation.com/our-clients/) - We have served over 81,000 satisfied customers. Our clients include investors (about 45%) and companies (about 55%). Have a look at our non-confidential list of investors and companies to get an idea of what we can do for you.
- [Valuation Process](https://venturevaluation.com/valuation-process/) - The complete valuation process takes around 3 to 5 weeks, including a workshop with our experts.
- [Services for Investors](https://venturevaluation.com/services-for-investors/) - Investment analysis and monitoring for fund managers, limited partners, shareholders, beneficiaries or holding companies is a key part of maintaining a successful investment portfolio. We assist you in easily monitoring the progress of your portfolio.
- [Product Valuation](https://venturevaluation.com/product-valuation/) - Understanding product and IP value, as well as the available licensing deal structures, is a prerequisite for licensing negotiations. For this reason, an independent product valuation report provides you with a solid basis for negotiation, and allows you to consider the key value inflection points in your product development plan as well as the financial impact of different deal arrangements. Furthermore, understanding the financial impact of upfront/milestone payments and royalties on licensing deals can also be useful tools in the negotiation process. We can help you to prioritize your products, analyze the risk/return for each project and compare the needed investment with the potential return.
- [Company Valuation](https://venturevaluation.com/company-valuation/) - Company valuation is a critical part of any business transaction and will be required for many reasons. Regardless of whether you seek to complete an investment, an Initial Public Offering (IPO) or a Merger & Acquisition (M&A), the valuation forms an integral part of negotiations and can ultimately determine the success of a given transaction.
- [Valuation Methods](https://venturevaluation.com/valuation-methods/) - In order to evaluate a company, an initial understanding of the valuation methods is essential. Therefore, at Venture Valuation, we pursue a holistic evaluation approach. All valuations are based on a careful consideration of both hard facts and soft factors.
- [Biotechgate](https://venturevaluation.com/biotech-gate/) - Biotechgate is a business development and licensing database for the life sciences industry. It covers over 65,000 companies and includes data about more than 800,000 clinical trials and 40,000 assets available for licensing. The platform gives you real-time information at your fingertips on the Biotech, Pharma, Medtech, Digital Health and other life sciences sectors.
- [Privacy Policy](https://venturevaluation.com/privacy-policy/) - Privacy & Cookie Policy
- [Partner Search](https://venturevaluation.com/partner-search/) - Finding the right partner can be a time-consuming task and with limited company resources available, the task is extremely taxing. In addition, discretion and a level of secrecy can add an extra layer of complexity. The use of third-party professionals therefore becomes not only warranted but essential. Whatever the reasons, we help you find the right partners.
- [Our Team](https://venturevaluation.com/our-team/) - We are a global team combining years of experience and expertise in areas such as valuation consulting, business development, and data processing with a strong focus on the life sciences industry.
- [Events](https://venturevaluation.com/events/) - Upcoming events in the life science industry
- [Contact Us](https://venturevaluation.com/contact-us/) - We are happy to discuss your needs and advise you on solutions tailored to your project. Get in contact with us to request a sample valuation report, ask a question or find out more about our services. We look forward to hearing from you!

## Categories

- [Industry Reports](https://venturevaluation.com/category/reports-and-analyses/)
- [Presentations](https://venturevaluation.com/category/presentations/)
- [News](https://venturevaluation.com/category/press-releases/)
- [Other Documents](https://venturevaluation.com/category/other-documents/)
- [Interviews](https://venturevaluation.com/category/lets-interview-series/)
- [Whitepapers](https://venturevaluation.com/category/whitepapers/)
- [Biotechgate](https://venturevaluation.com/category/biotechgate/)
- [Docs](https://venturevaluation.com/category/docs/)

## Tags

- [jpm](https://venturevaluation.com/tag/jpm/)
- [life sciences](https://venturevaluation.com/tag/life-sciences/)
- [life science start-up](https://venturevaluation.com/tag/life-science-start-up/)
- [valuation](https://venturevaluation.com/tag/valuation/)
- [hbs](https://venturevaluation.com/tag/hbs/)
- [harvard business school](https://venturevaluation.com/tag/harvard-business-school/)
- [life science startup valuation](https://venturevaluation.com/tag/life-science-startup-valuation/)
- [patrik frei](https://venturevaluation.com/tag/patrik-frei/)
- [harvard business school healthcare alumni](https://venturevaluation.com/tag/harvard-business-school-healthcare-alumni/)
- [CLSA](https://venturevaluation.com/tag/clsa/)
- [california life sciences](https://venturevaluation.com/tag/california-life-sciences/)
- [usa life sciences](https://venturevaluation.com/tag/usa-life-sciences/)
- [clsa partners](https://venturevaluation.com/tag/clsa-partners/)
- [PeptiDream](https://venturevaluation.com/tag/peptidream/)
- [Kiichi Kbota](https://venturevaluation.com/tag/kiichi-kbota/)
- [PDPS](https://venturevaluation.com/tag/pdps/)
- [peptide drug technology](https://venturevaluation.com/tag/peptide-drug-technology/)
- [BIO IP & Diagnostics Symposium](https://venturevaluation.com/tag/bio-ip-diagnostics-symposium/)
- [IPDx keynote speech](https://venturevaluation.com/tag/ipdx-keynote-speech/)
- [RESI Conference](https://venturevaluation.com/tag/resi-conference/)
- [RESI Boston](https://venturevaluation.com/tag/resi-boston/)
- [Redefining Early Stage Investments](https://venturevaluation.com/tag/redefining-early-stage-investments/)
- [masschallengeCH](https://venturevaluation.com/tag/masschallengech/)
- [startup valuation](https://venturevaluation.com/tag/startup-valuation/)
- [pre-valuation assessment](https://venturevaluation.com/tag/pre-valuation-assessment/)
- [startup value assessment](https://venturevaluation.com/tag/startup-value-assessment/)
- [masschallenge lausanne](https://venturevaluation.com/tag/masschallenge-lausanne/)
- [antibiotics market](https://venturevaluation.com/tag/antibiotics-market/)
- [antibiotics financing](https://venturevaluation.com/tag/antibiotics-financing/)
- [invest in antibiotics](https://venturevaluation.com/tag/invest-in-antibiotics/)
- [find investors in antibiotics](https://venturevaluation.com/tag/find-investors-in-antibiotics/)
- [antibiotics market overview](https://venturevaluation.com/tag/antibiotics-market-overview/)
- [HERV](https://venturevaluation.com/tag/herv/)
- [geneuro sa](https://venturevaluation.com/tag/geneuro-sa/)
- [jesús martin-arcia geneuro](https://venturevaluation.com/tag/jesus-martin-arcia-geneuro/)
- [human endogenous retroviruses](https://venturevaluation.com/tag/human-endogenous-retroviruses/)
- [RESI San Diego 2017](https://venturevaluation.com/tag/resi-san-diego-2017/)
- [Redefining Early Stage Investments San Diego 2017](https://venturevaluation.com/tag/redefining-early-stage-investments-san-diego-2017/)
- [Valuation workshop resi san diego 2017](https://venturevaluation.com/tag/valuation-workshop-resi-san-diego-2017/)
- [life science valuation](https://venturevaluation.com/tag/life-science-valuation/)
- [medtech valuation](https://venturevaluation.com/tag/medtech-valuation/)
- [biotech valuation](https://venturevaluation.com/tag/biotech-valuation/)
- [obseva obstetrics and beyond](https://venturevaluation.com/tag/obseva-obstetrics-and-beyond/)
- [Dr. Ernest Loumaye obseva](https://venturevaluation.com/tag/dr-ernest-loumaye-obseva/)
- [advanced reproductive and pregnancy therapeutics](https://venturevaluation.com/tag/advanced-reproductive-and-pregnancy-therapeutics/)
- [Designing The Future in Life Sciences](https://venturevaluation.com/tag/designing-the-future-in-life-sciences/)
- [How will life sciences look like](https://venturevaluation.com/tag/how-will-life-sciences-look-like/)
- [future of life sciences](https://venturevaluation.com/tag/future-of-life-sciences/)
- [BioAlberta](https://venturevaluation.com/tag/bioalberta/)
- [Alberta life sciences](https://venturevaluation.com/tag/alberta-life-sciences/)
- [Alberta biotech](https://venturevaluation.com/tag/alberta-biotech/)
- [life sciences british columbia](https://venturevaluation.com/tag/life-sciences-british-columbia/)
- [life sciences bc](https://venturevaluation.com/tag/life-sciences-bc/)
- [british columbia life science companies database](https://venturevaluation.com/tag/british-columbia-life-science-companies-database/)
- [bc life science companies database](https://venturevaluation.com/tag/bc-life-science-companies-database/)
- [biotech trends 2018](https://venturevaluation.com/tag/biotech-trends-2018/)
- [early stage biotech deals](https://venturevaluation.com/tag/early-stage-biotech-deals/)
- [biotech investments 2018](https://venturevaluation.com/tag/biotech-investments-2018/)
- [Quebec Life Science Directory](https://venturevaluation.com/tag/quebec-life-science-directory/)
- [Quebec biotech directory](https://venturevaluation.com/tag/quebec-biotech-directory/)
- [Montreal in ViVo directory](https://venturevaluation.com/tag/montreal-in-vivo-directory/)
- [side selection](https://venturevaluation.com/tag/side-selection/)
- [biotech](https://venturevaluation.com/tag/biotech/)
- [JP Morgan Conference](https://venturevaluation.com/tag/jp-morgan-conference/)
- [JPM Conference](https://venturevaluation.com/tag/jpm-conference/)
- [JP Morgan Healthcare week](https://venturevaluation.com/tag/jp-morgan-healthcare-week/)
- [JPM healthcare week](https://venturevaluation.com/tag/jpm-healthcare-week/)
- [JPM San Francisco](https://venturevaluation.com/tag/jpm-san-francisco/)
- [GTAI](https://venturevaluation.com/tag/gtai/)
- [Health Made in Germany](https://venturevaluation.com/tag/health-made-in-germany/)
- [German Biotech](https://venturevaluation.com/tag/german-biotech/)
- [German Life Sciences](https://venturevaluation.com/tag/german-life-sciences/)
- [Ferring Pharmaceutical](https://venturevaluation.com/tag/ferring-pharmaceutical/)
- [product valuation](https://venturevaluation.com/tag/product-valuation/)
- [asset valuation](https://venturevaluation.com/tag/asset-valuation/)
- [in-licensing opportunities](https://venturevaluation.com/tag/in-licensing-opportunities/)
- [Biotechgate](https://venturevaluation.com/tag/biotechgate/)
- [life science database](https://venturevaluation.com/tag/life-science-database/)
- [clinical trial database](https://venturevaluation.com/tag/clinical-trial-database/)
- [409A valuation](https://venturevaluation.com/tag/409a-valuation/)
- [AOT](https://venturevaluation.com/tag/aot/)
- [Cyrill Bätscher](https://venturevaluation.com/tag/cyrill-batscher/)
- [Cold Ablation Robotguided Laser Osteotome](https://venturevaluation.com/tag/cold-ablation-robotguided-laser-osteotome/)
- [cranio-maxillofacial surgery](https://venturevaluation.com/tag/cranio-maxillofacial-surgery/)
- [medical image analysis](https://venturevaluation.com/tag/medical-image-analysis/)
- [AI Medical Service](https://venturevaluation.com/tag/ai-medical-service/)
- [Tomohiro Tada](https://venturevaluation.com/tag/tomohiro-tada/)
- [early digestive track cancer detection](https://venturevaluation.com/tag/early-digestive-track-cancer-detection/)
- [Rhine-Main-Neckar biotech](https://venturevaluation.com/tag/rhine-main-neckar-biotech/)
- [NeU Corporation](https://venturevaluation.com/tag/neu-corporation/)
- [brain activity measuring](https://venturevaluation.com/tag/brain-activity-measuring/)
- [Kiyoshi Hasegawa](https://venturevaluation.com/tag/kiyoshi-hasegawa/)
- [XB-01](https://venturevaluation.com/tag/xb-01/)
- [Biotechgate Digital Partnering](https://venturevaluation.com/tag/biotechgate-digital-partnering/)
- [HelloPartnering](https://venturevaluation.com/tag/hellopartnering/)
- [Shiho Azuma](https://venturevaluation.com/tag/shiho-azuma/)
- [Lily MedTech Inc.](https://venturevaluation.com/tag/lily-medtech-inc/)
- [breast cancer](https://venturevaluation.com/tag/breast-cancer/)
- [breast ultrasound diagnostic imaging system](https://venturevaluation.com/tag/breast-ultrasound-diagnostic-imaging-system/)
- [BIA Life Science Leadership Summit](https://venturevaluation.com/tag/bia-life-science-leadership-summit/)
- [asian life sciences](https://venturevaluation.com/tag/asian-life-sciences/)
- [KMPG](https://venturevaluation.com/tag/kmpg/)
- [FRONTEO](https://venturevaluation.com/tag/fronteo/)
- [Yamamoto Mari](https://venturevaluation.com/tag/yamamoto-mari/)
- [Toyoshiba Hiroyoshi](https://venturevaluation.com/tag/toyoshiba-hiroyoshi/)
- [big data analysis](https://venturevaluation.com/tag/big-data-analysis/)
- [NLP AI](https://venturevaluation.com/tag/nlp-ai/)
- [Norway Healthtech](https://venturevaluation.com/tag/norway-healthtech/)
- [Valuation Experts](https://venturevaluation.com/tag/valuation-experts/)
- [Norway Health Tech](https://venturevaluation.com/tag/norway-health-tech/)
- [elias neuendorf](https://venturevaluation.com/tag/elias-neuendorf/)
- [RESI](https://venturevaluation.com/tag/resi/)
- [Forty51 Ventures](https://venturevaluation.com/tag/forty51-ventures/)
- [Sascha Oliver Bucher](https://venturevaluation.com/tag/sascha-oliver-bucher/)
- [Investment](https://venturevaluation.com/tag/investment/)
- [Biotech firms](https://venturevaluation.com/tag/biotech-firms/)
- [Funding](https://venturevaluation.com/tag/funding/)
- [Gergely Ivanyi](https://venturevaluation.com/tag/gergely-ivanyi/)
- [Yone Production Co Ltd](https://venturevaluation.com/tag/yone-production-co-ltd/)
- [Fujieda Ayumi](https://venturevaluation.com/tag/fujieda-ayumi/)
- [Cells](https://venturevaluation.com/tag/cells/)
- [filming](https://venturevaluation.com/tag/filming/)
- [SARS CoV 2](https://venturevaluation.com/tag/sars-cov-2/)
- [Virus](https://venturevaluation.com/tag/virus/)
- [destroyed](https://venturevaluation.com/tag/destroyed/)
- [Therapy](https://venturevaluation.com/tag/therapy/)
- [heart](https://venturevaluation.com/tag/heart/)
- [cell therapy](https://venturevaluation.com/tag/cell-therapy/)
- [cardiac remuscularization](https://venturevaluation.com/tag/cardiac-remuscularization/)
- [Heartseed Inc.](https://venturevaluation.com/tag/heartseed-inc/)